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 “Study of significance of echocardiography in thalassemia 
major/intermedia patients at tertiary care centre”ICh&HC, 
Chennai. 
Usha B K*, Ravichandran T. Gnanasambandam S. 
 AIM OF THE STUDY: 
           To study the cardiovascular complications in transfusion dependent beta thalassemia 
major/intermedia  patients  and to establish the significance of echocardiography  in them. 
MATERIALS & METHODS 
 This descriptive study was done on transfusion dependent thalassemia major / intermedia 
patients in the age group of 2 to 12 years on regular chelation therapy coming to ICH and HC, 
Chennai. Patients with a known congenital heart disease or terminal illness were excluded. 
A detailed history including symptoms, age at diagnosis, consanguinity, sibling history was 
taken. Blood for complete blood count and serum ferritin was taken and patients were subjected 
to electrocardiography, 2D and M-mode echocardiography  and continous wave  Doppler. 
Patients were divided into two groups based on Hb electrophoresis into TM and TI .The ecg and 
echocardiographic findings of these patients were compared. Patients were further categorized 
on serum ferritin values as those with >1000ng/dl and <1000ng/dl and it was studied with ecg 
and echocardiographic findings 
RESULTS: 
24 %(n=13) thalassemia patients have pulmonary hypertension. Incidence of pulmonary 
hypertension was high in TI(42%) than TM(21%) in our study. LV mass and LV mass index 
was increased in 63% of patients. Serum ferritin values did not correlate with the LVmass/m2, 
pulmonary hypertension and cardiac dysfunction on echocardiography. 
QT c was normal and arrhythmias was not seen on ecg in our study. 
CONCLUSIONS: 
Echocardiography can be used as screening tool in asymptomatic thalassemia patients. Serum 
ferritin is not a good indicator of cardiac toxicity secondary to iron. Cardiac MRI is the gold 
standard for detection of cardiac iron load. 
RECOMMENDATIONS: Echocardiography can be used as a screening tool and periodic 
follow up for cardiac complications in thalassemia patients. 
Key words:  thalassemia major, intermedia, echocardiography,  
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INTRODUCTION 
Anemia is defined as decrease in the total circulating erythrocytes below 
the normal limit for the corresponding age. It causes reduced oxygen carrying 
capacity of blood causing tissue hypoxia8,16. The normal cut off values for 
hemoglobin content and red cell volume differs for race, age and sex. Anemia 
is a public health problem and has high prevalence in Asian and African 
countries5. 
Etiology of anemia in this region is mainly due to3 
- Nutritional causes 
- Infectious causes 
- Genetic disorders involving hemoglobin synthesis 
Thalassemia is the most common type of hemolytic anemia seen 
worldwide, the term is derived from Greek word– thalassa meaning the sea, 
and emia meaning weak blood or anemia. Professor Thomas Cooley first 
described this condition in Italian patients. George Hyot Whipple and Bradford 
coined the term thalassemia51. 
It is group of inherited disorders having defective synthesis of one or 
more of globin chains. It has an autosomal recessive inheritance. Carriers of 
thalassemia are asymptomatic individuals4, there is 25 percent chance of having 
an affected baby when both parents are carriers and when a single parent is 
carrier it is zero percent .It is a quantitative abnormality of synthesis of the 
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polypeptide chains. Based on the impairment of the globin chain, thalassemia is 
classified as alpha or beta thalassemia respectively 
EPIDEMIOLOGY: 
As per WHO, 7 percent of world’s population are estimated to be 
carriers of hemoglobinopathies5. It is the most common single gene disorder 
found worldwide affecting millions of human beings, more commonly in 
malaria endemic region. Prevalence of monogenic disorders globally is 
10/1000. 
 
 
Alleles of thalassemias are carried by 3 % of the world`s population5,16. 
And in South East Asia alone 5 to 10 % of abnormal alleles are carried for 
alpha thalassemias . Alpha thalassemia is seen most commonly in China and 
South East Asia and less frequently in Kuwait, Middle east, Northern Europe, 
Italy and India where β thalassemia is more8. Immigration and marriage 
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between communities has lead to the spread of thalassemia even in European 
and American countries which are not endemic for malaria. 
About 50,000 to 100,000 children in middle and low income countries 
die every year with thalassemia major.  
THALASSEMIA IN INDIA: 
In India the burden of this disease is high with about 12,000 babies born 
with thalassemia major each year. Carrier rate is 1 to 17 %( average is 3.2%). 
Distribution varies in different parts of the country. Prevalence is high in 
Punjab, Sindhis in north India4,7. 
Though a preventable disease, the financial burden of blood 
transfusions, mortality and morbidity associated with the disorder is high. 
Cardiac complications are the most common cause of death in thalassemia 
patients. Without management by blood transfusions, these children usually die 
in the first few years of life. They develop severe anemia and hyperdynamic 
circulation, followed by congestive cardiac failure and death. Before the advent 
of iron chelation therapy chronic severe anemia and iron over load were the 
primary causes for cardiomyopathy and mortality in thalassemia patients. 
Increased incidence of pulmonary hypertension and arrhythmia is seen in these 
patients compared to the general population11. With the introduction of blood 
transfusions and chelation therapy the morbidity and deaths have been pushed a 
decade later. The survival and life expectancy has improved32. 
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Clinically, it is difficult to diagnose symptoms of heart failure as they 
overlap with the symptoms of pre existing anemia. Many symptoms that are 
seen in anemia like increased heart rate, easy fatiguability, exertional dyspnoea, 
liver enlargement are also seen in heart failure. Hence these patients need 
continuous monitoring of symptoms and signs aided with investigations for 
early detection of complications and its management for better outcome. 
To detect this pre symptomatic stage of cardiac complications many 
techniques are available in India like electrocardiogram, echocardiography, T2 
cardiac MRI, MUGA scanning. Ecg and echocardiography are cost effective, 
non invasive and easily available in many parts of the country. However the 
gold standard to assess the cardiac iron overload is by magnetic resonance 
imaging which is expensive, time consuming and requires highly skilled 
personnel for the procedure.  
Hence many studies are done to know the sensitivity and specificity of 
these two investigations in detecting early cardiac involvement in thalassemia 
patients. The goal is to have an investigation tool which is less expensive, 
easily available and can also give accurate results.  
Thalassemia is a group of genetic disorder with defective globin chain 
synthesis. It is characterized by varying degrees of ineffective erythropoesis. 
Mutations of β – globin genes occur predominantly in children of 
Mediterranean , Southern, and Southeast Asian ancestry16. Clinically 
thalassemia is classified into α and β thalassemias, each with varying degrees 
of α and β chains mutated. Abnormality in beta globin chain synthesis causes β 
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thalassemia due to point mutations in one or two of the beta globin genes. 
Though more than 60 beta thalassemia mutations are seen in our country, only 
five types(IVS 1-5,619-bp deletion, IVS 1-1. FS8/9, FS41/42) account for 
majority of the cases4. 
To know the pathophysiology of anemia in thalaseemia and iron 
overload an overview of hemoglobin synthesis and iron metabolism is 
necessary. 
SYNTHESIS OF HAEMOGLOBIN 
Adult hemoglobin is made of two α and two β chains. Thalassemia is 
due to the failure in switching over from fetal to adult hemoglobin resulting in 
excessive fetal hemoglobin and low levels of hemoglobin A along with A219. 
Synthesis of hemoglobin starts in pro erythroblasts and proceeds to 
reticulocyte phase of erythrocytes. A pyrrole molecule is formed after succinyl 
CoA binds with glycine. 4 pyrroles join to give protoporphyrin IX. Heme 
molecule is formed once protoporphyrin IX combines with iron. This heme 
now combines with polypeptide to form either a α or β chain. 2 α and 2 β chain 
constitute a tetramer of hemoglobin A molecule. α chain is made up of 141 AA 
& β chain is made up of 146 AA. Molecular weight of each chain is about 
16,000. Molecular weight of hemoglobin A is 64,458. 
Based on amino acid in the polypeptide part of hemoglobin , there are 4 
types of globins chains alpha, beta, gamma , delta chains. 
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One molecule of haemoglobin carries eight oxygen atoms , each iron 
atom binds with 2 atoms of oxygen. This is important as the oxygen binding 
capacity of haemoglobin is dependent on the type of globin chain it contains. 
Molecular oxygen binds loosely and reversibly with iron so that, it is released 
at tissue capillaries. 
GENETICS 
 Pseudo genes which are inactive are implicated in the pathogenesis of 
thalassemia.α and β globin genes are located on the short arm of 16 
and 11 chromosome respectively. 
 Following functional genes, ε, γ, Aγ, δ and β are seen in β-like 
cluster. They are arranged in 5’ to 3’. 
 Embryonic E gene codes for Hb Gower1 and Hb Gower 2. 
 Delta globin gene which codes for Hb A2 differs only in 10 residues 
in comparison with β -globin gene. 
 Adult Hb comprises of two 2α and 2β globin chains. 
 Fetal hemoglobin synthesis starts when erythropoeisis occurs in liver 
during fetal life. 
 When erythropoeisis switch occurs from liver in fetal life to bone 
marrow at about 20wks of gestation, there will be transition in 
production of Hb F to Hb A. 
However this switch is related to time of gestation rather than site of 
erythropoeisis8,16,18.  
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MOLECULAR PATHOGENESIS 
Clinical syndrome Genotype Molecular genetics 
B- Thalassemia major 
Homozygous β-
thalassemia ( β 0 /β 0, β + / 
β +,β 0 β +) 
Point mutations cause 
abnormalities in 
transcription splicing or 
translation of B- globin 
mRMA 
B- Thalassemia 
intermedia 
Variable (β0 /β+ ,β+/β+ 
,β0/ β+, β+ / β )  
Point mutations cause 
abnormalities in 
transcription splicing or 
translation of B- globin 
mRNA 
B- Thalaseemia minor 
Heterozygous β- 
Thalassemia β0/β, β+/β 
 
α Thalaseemia   
Hydrops fetalis  -/- -/- Gene deletions 
HbH disease -/- -/α Gene deletions 
α thalassemia trait -/- α/α, -/α, -/α Gene deletions 
Genetic Classification of Thalassemias16 
 
β- thalassemia is due to mutation which decreases the production of β –
globin chains. The clinical picture varies secondary to the heterogeneity of 
mutation, that can be βo mutation or β+ mutation18.  
βo – total absence of β-globin chains 
β+ decreased amount β-globin chains  
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Though over hundreds of causative mutations are implemented in β- 
thalaseemia, few important ones are mentioned here16. 
 Splicing mutations:- mostly seen in β+ thalaseemia, predominantly in 
introns when there is partial absence of β globins. In βo thalassemia, the 
mutations completely stop the normal β-globin mRNA production since 
they destroy normal splice functions in the RNA. 
 Promoter region mutations:- β+ that are mostly associated with these 
mutations. Here the transcription is decreased by 80%. 
 Chain terminator type of mutations seen mostly associated with βo 
thalassemia.  
Two types of mutations [(i) introduction of new stop codon in exons, (ii) 
frameshift mutation within the exons occur to block translation leading to 
absence of β-globin chains. 
FATE OF RBC 
Life span of erythrocytes is 120 days. RBCs contain enzymes which 
maintain 
 transport of ions. 
 pliability of erythrocyte membrane 
 iron in ferrous form and proteins unoxidised. 
Fragile red blood cells breakdown while passing through spleen and 
release hemoglobin which is phagocytosed mostly by liver, spleen and bone 
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marrow, where macrophages release iron. This free iron is carried by the 
transport protein transferrin for production of new erythrocytes or converted 
into storage form ferritin in liver, cardiac and other sites.. Bilirubin form 
biliverdin is secreted through bile. 
IRON METABOLISM 
Total amount of iron in human body is about 4 to 5 grams of which 65 
percent is hemoglobin, and myoglobin is 4 percent, 0-1percent combines with 
transferrin and 30 percent is in the storage form ferritin in liver, spleen19. 
TRANSPORT AND STORAGE OF IRON 
 
 
  
Fe 2+ + Apotransferrin
feces(iron)
Transferrin
FREE IRON
FERRITIN 
PLASMA
TISSUES 
Enzymes
Heme
Haemosiderosis
HAEMOGLOBIN
in RBC
Mitochondria
Blood Loss
Hb
degradation 
to free iron 
inside 
macrophages
Macrophages
Bilirubin
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Iron absorption: 
Iron metabolism is unique. The absorption of iron plays a major role and 
excretion of iron has minor role to maintain iron balance. There is no 
mechanism for excretion of iron other than desquamation of epithelial cells 
from skin, intestine and urinary tract. Menstruation and pregnancy is a major 
cause of loss of iron in females. 
About 5 % to 10 % (0.5 to 1mg) of the dietary iron is absorbed from the 
body. This can increase to as high as 20 % in state of iron deficiency that is 
equal to 3 to 4 mg per day. Heme iron is better absorbed than non heme iron. 
And presence of heme iron increases absorption of non heme iron. 
Iron is absorbed in the small intestine mainly in proximal duodenum. 
Ferrous form is better absorbed than ferric form. Gastric acid enhances the 
absorption of iron. Heme iron is absorbed more efficiently than inorganic iron, 
independent of duodenal pH. There are number of factors which influence iron 
absorption from the instestine. After iron enters the intestine it can be retained 
inside the cell and lost once enterocyte is sloughed or transported across the 
basolateral membrane to enter the body. Iron retained in the enterocyte will be 
incorporated into ferritin.  
Inside the cell, iron binds to unidentified carrier molecule which assist in 
delivery to various intracellular locations, such as mitochondria (heme 
synthesis) and ferritin (for storage). Iron in transit in the cell at any point of 
time is small. This minute pool of transit iron, is in the Fe2+ form, is 
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biologically active and considered to be potentially toxic form. Iron stored in 
ferritin and hemosiderin , is nontoxic and metabolically inactive. 
Iron is stored inside the body by binding with the ubiquitous cytosolic 
protein Ferritin . this stored iron will be released in a controlled manner 
depending on demand. It plays the role of a buffer between iron deficiency and 
iron overload. Ferritin in the serum, functions as carrier for iron. Plasma ferritin 
is can be used as an indirect marker of the body iron stores. Low levels of 
hepcidin and iron load can cause organ damage. 
Ferritin, a globular protein is made of 24 subunits. When not bound with 
iron ferritin is known as apoferritin. 
 
STRUCTURE OF FERRITN 
In reticuloendotheial cell iron is also stored as hemosiderin. Ferritin is 
increased in condition of iron over load such as thalassemia , hemochromatosis 
. 
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Ferritin being an acute phase reactant and level of ferritin can be falsely 
high in following condition. 
 Inflammation. 
 Infection. 
The normal range of ferritin is usually between 30–300 ng/mL. 
Secondary hemochromatosis is a well known complication in thalassemia 
patients who are on chronic blood transfusion. About 200 mg of iron will be 
transfused into the body with 250 ml of blood. After about 100 or more 
transfusions, cardiac dysfunction is documented to occur in thalassemia patient. 
Serum ferritin increases after 10-12 transfusions in un chelated patients. 
Estimation of serum ferritin is the traditional way of determining the iron 
overload54,55.  
B- THALASSEMIA – PATHOPHSIOLOGY: 
β- globin chain production is either decreased or completely absent 
causing an increase in α chains relatively. It leads to low levels of Hb and 
altered synthesis of globin chains.The sequelae of β thalassemia major is due to 
two related features. Low levels of normal hemoglobin A secondary to 
inadequate β globin gene synthesis and unbalanced production of α and β 
globin chains. 
In β thalassemia major, there is absence of β globin chains which causes 
a relative increase in α chains compared to non – alpha chains. These excess α 
tetramers are seen as inclusion bodies in erythroid precursors. The α globin 
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chains are unstable and precipitate in erythroid precursors causing damage to 
the cell membrane, shortens the life span of erythrocyte leading to anemia. This 
leads to significantly elevated erythropoiesis with death of red cell precursors 
in bone marrow. 
CLINICAL FEATURES: 
THALASSEMIA MAJOR 
Homozygous states usally present by 2 months to two years of age with 
severe pallor, failure to gain weight, growth retardation, cachexia, 
hepatosplenomegaly. These patients will require chronic blood transfusions and 
iron chelators8. 
Poorly transfused children have ineffective erythropoiesis features seen 
as increased metabolic needs, extramedullary hematopoeisis and expansion of 
marrow spaces16. 
Ineffective erythropiesis causes expanded medullary spaces of facial and 
skull bones causing frontal and parietal bone bossing, depressed nasal bridge, 
prominent malar eminence, malocclusion of maxillary teeth giving a chipmunk 
or thalassemic facies. Deformities of bones are seen secondary to marrow 
expansion. Un transfused patients can have significant splenomegaly with 
features of hypersplenism. Abdominal symptoms are also seen. 
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THALASSEMIA INTERMEDIA: 
These patients have a heterozygous state. Clinically have less pallor and 
remain asymptomatic till about two years of age. They may require blood 
transfusions. 
THALASSEMIA MINOR 
These patients have a heterozygous states. Clinically symptoms are 
minimal, affected children usually have mild anemia which does not respond to 
iron supplements .HbA2 is more than 3.4%.They can lead a normal life, and do 
not require regular blood transfusions. 
COMPLICATIONS: 
Can be due to chronic anemia and tissue hypoxia. Iron overload 
secondary to increased gut absorption and high levels of erythropoietin. Cardia 
complications are most common. 
CHRONIC ANEMIA: the children present with increasing pallor, 
decreased activity, failure to thrive, impaired exercise tolerance, abdominal 
pain, signs of cardiac failure. 
CARDIOMYOPATHY IN THALASSEMIA: The most common 
cause of mortality in transfused patients of TM is heart failure mainly to 
cardiac iron overload. The pathology in thalassemia is not just the hemolysis 
and iron overload, but the adaptation of heart to the long standing anemia. 
Chronic anemia has symptoms like breathlessness and exercise intolerance 
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which can mask the clinical diagnosis of failure. Cardiac adaptations to chronic 
anemia can be seen as tachycardia at rest, low blood pressure, increased end 
diastolic volume, increased ejection fraction and cardiac output that is high. 
Cardiac disease in β thalassemia is most commonly seen as a 
cardiomyopathy which progresses to heart failure and death. It is 
phenotypically charaterised into- 
 Dialated type : dilatation of left ventricle and decreased 
contractility 
 Restrictive type: left ventricular filling defect, heart failure 
preceded by pulmonary hypertension 
PATHOPHYSIOLOGY: Tt is complex , however the following 
factors are responsible for cardiac complications2 
 Chronic hypoxia of tissues secondary to long standing anemia. 
 Due to the increased levels of fetal hemoglobin having high oxygen 
affinity and low levels of 2,3 di phosphoglycerate in donor blood. 
 Intrasplenic shunts and liver damage due to extramedullary 
hematopoeisis increasing the cardiac output. 
 Iron overload in heart is thought to be the most common cause of 
myopathy in thalassemia patients. Free oxygen radicals from Fenton 
and Haber-Weiss reaction (redox reaction converting ferrous to ferric) 
are known to cause iron toxicity. 
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This free iron present in circulation once transferrin is saturated, is labile 
and through voltage dependant L – type calcium channels enters the cardiac 
myocyte in ferrous form. This ferrous iron causes apoptosis of cardiac 
myocytes and ultimately cardiac dysfunction. 
 Iron overload increases the susceptibility of myocarditis secondary to 
viral infections. 
 Immunological theory: patients of thalassemia major with heart failure 
are known to be frequently associated with HLA-DQA1*0501 allele. 
Whereas patients without heart failure are seen most frequently 
associated with HLADRB* 1401 allele which is cardioprotective. 
PULMONARY HYPERTENSION (PH) IN THALASSEMIA PATIENTS: 
 DEFINITION : PH is defined as a mean pulmonary artery pressure of 
25 mm of Hg or above in an individual at rest at the sea level31. 
 It is a complication seen commonly in thalassemia patients. Reduced 
nitric oxide availability, endothelial dysfunction, hypercoagubility, 
increased stiffness of arteries and pulmonary vascular resistance are all 
implicated in the complex multifactorial etiology of pulmonary 
hypertension in thalassemia patients11,14. 
 Low hemoglobin levels in TM patients causes a chronic hypoxia20 
condition that can lead to active pulmonary vascular damage. In the 
hypoxia setting, smooth muscle cells of the pulmonary vasculatur are 
depolarized by the downregulation of potassium membrane channels. 
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This causes an increase in intracellular calcium levels which enhances 
the cellular response to vasoconstrictors. This chain of anemia, hypoxia, 
vasoconstriction, injury to endothelium, proliferation of smooth muscles 
and obliteration of pulmonary vasculature reoccur many times in 
thalassemia patients which ultimately causes pulmonary hypertension. 
 Diagnosis of PH in thalassemic patients requires regular and periodic 
screening as majority of them are asymptomatic, even, a normal 
systemic blood pressure is seen in patients when the pulmonary 
pressures are recorded high. 
 Frequent blood transfusions cause iron overload in cardia, liver, lung 
and spleen. Free radical injury due to iron in lungs is also postulated as a 
possibility for development of pulmonary hypertension by 
immunoinflammatory pathway. Iron toxicity also causes cirrhosis of 
liver which can cause PH21. 
 Increased levels of vasoconstrictor endothelin –I, low levels of NO 
synthase which leads to low level of NO, and high level of arginase 
(substrate for NO synthesis) secondary to chronic hemolysis and 
hypoxia in TM lead to pulmonary vasoconstriction.  
Various techniques are used to find presymptomatic cardiac 
complications. They are echocardiography with tissue Doppler Imaging, T2* 
cardiac MRI, and MUGA scanning. 
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TRANSFUSIONAL HEMOSIDEROSIS: 
Frequent blood transfusions is associated with infections, febrile 
reactions iron accumulation. One unit of packed red blood cells has 250-300 
mg of iron(1mg/ ml). Iron accumulates in chronically transfused children as 
excretion does not occur .In one transfusion of two units iron accumulated is 
equal to one year oral intake of iron.  
Secondary hemochromatosis in thalassemia is because of inappropriate 
red cell production, increased hemolysis, defective hemoglobin and increased 
absorption of iron from gastrointestinal tract. After one year of regular blood 
transfusions iron starts to accumulate in liver followed by the endocrine glands. 
It takes about ten years for cardiac decompensation to occur due to iron 
overload21. 
ENDOCRINE DISTURBANCES: 
Iron gets deposited in ferritin form in liver, pancreas, endocrine glands 
skin heart and other tissues35,36. Endocrine disturbances like hypothyroidism, 
diabetes mellitus, hypoparathyroidism, hypogonadism and hypopituitarism is 
seen . Short stature can be seen as well36,37. 
OSTEOPOROSIS: 
Patients of thalassemia who are dependant on blood transfusions have 
increased frequency of osteoporosis and osteopenia38,39. It can be secondary to 
endocrine disturbances like hypothyroidism and hypoparathyroidism also. 
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Desferrioxamine chronic ingestion causes disc disease. It is usually seen in 
second decade40. 
These children present with fractures, low back ache , short stature, 
bony deformities. 
INFECTIONS: 
Complications associated with blood transfusions is infections like, 
HIV, CMV, hepatitis B and hepatitis C. Opportunistic infections are seen due 
to iron overload. Yersinis entercolitica grows well with excessive iron .Clinical 
features are fever and diarrhea41. It can be treated with cotrimaxazole and 
aminoglycosides. Infections caused by Listeria monocytogenes and Rhizopus 
oryzae is also seen commonly in thalassemia patients. Following spleenectomy 
these children are highly susceptible for developing infections by capsular 
micro organisms.  
Other complications are gall stones, hepatocellular carcinoma, gout 
secondary to hyperuricemia42. 
PSYCHO/SOCIAL FACTOR 
Repeated and frequent transfusions tamper the quality of life. Chronic 
illness impairs the psycho social stability and leads to poor complaince. Due to 
these factors, thalaseemia has a negative impact on HRQOL(Health Related 
Quality of Life)43. 
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Children with multiple transfusions have increased prevalence of 
problems related to behaviour. Hemosiderotic patients are known to have 
impaired abstract, remain attention deficit, have poor memory, defect of 
language, constructional, visual spatial skills44,45,46. 
INVESTIGATIONS:  
1. Complete blood count: Hemoglobin is normal to severely reduced. MCV, 
MCH, MCHC will be reduced.  
2. Peripheral blood smear: Shows marked microcytic hypochromic anemia, 
anisopiokiocytosis, polycytosis, nucleated cells, target cells, pencil cells, 
basophilic stippling, rarely immature WBCs. 
3. Red cell distribution width (RDW) is increased indicating anisocytosis. 
4. Reticulocyte count: Reticulocytosis is seen as marker of increased 
erythopoiesis due to increased hemolysis. Corrected reticulocyte count 
more than 2.5 % is taken as evidence of increased bone marrow activity. 
Due to ineffective erythopoiesis in the bone marrow it will be less than 
8%. 
5. Mentzers Index: Mentzer index helpful in differentiating iron deficiency 
anemia from beta thalassemia. The index is calculated from the quotient 
of the mean corpuscular volume (MCV) divided by the red blood cell 
count (RBC). If the value is less than 13 thalassemia is probable diagnosis 
and if its more than 13 it indicates towards iron deficiency anaemia27. 
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6. An elevated LDH and unconjugated bilirubin is usually seen indicating 
ineffective erythopoiesis. Serum iron and ferritin is elevated. 
7. X-ray showing widening of medulla due to bone marrow hyperplasia 
thinning of cortex and long bones show trabeculation, including the 
metacarpals and meta tarsals. 
8. Hemoglobin electrophoresis: Using this test we can classify into 
thalassemia major, intermedia and minor based on the level of HbA, HbF 
& Hb A2.  
9. Ultrasound abdomen : for confirmation of hepatosplenomegaly. 
10. Genetic analysis : It helps to know the type of mutation and classification 
of thalassemia. 
ECHOCARDIOGRAPHY: 
Echocardiography is the most commonly used non invasive technique 
for systolic and diastolic functions, ventricular size assessment, and evaluation 
for pulmonary arterial hypertension. Pericarditis and valvular involvement can 
also be picked up. 
These parameters are included in echocardiography 2D and M-mode: It 
is used primarily for measurement of ventricular dimensions like wall thickness 
and size, systolic functions ,fractional shortening and motion abnormalities of 
cardiac valves.  
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Doppler Echocardiography: it is a combination study of blood flow 
profiles with the cardiac pictures. Two methods commonly done are pulsed 
wave and continuous wave. The velocity of tricuspid and pulmonary 
regurgitant jets and its severity can be assessed by this technique29.  
MAGNETIC RESONANCE IMAGING: 
It is the gold standard for evaluation of cardiac iron load. It provides a 
quantitive ventricular function, tissue characterization, viability of the 
myocardium. Cardiac MRI assessment of T2* and ejection fraction on yearly 
basis is best in a good set up. Cardiac T2* is useful for cardiac iron load 
assessment, it is the time taken for decay of myocardial signal by 63% and is 
measured im ms( milliseconds). Based on it risk of cardiac iron load is divided 
into low , intermediate and severe when it is >20ms,10-20ms,and <10ms 
respectively.It can assess the preclinical cardiac dysfunction. 
It does not have operator variability, however cost and non availabilty in 
resource poor setting are disadvantages for wide use29. 
TRANSFUSION THERAPY 47,48,49 
Blood transfusion is indicated when 
i. Hb < 7gm/dl 
ii. Features s/o extramedullary erythropoiesis like facial 
changes 
iii. Inadequate growth & fractures  
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Prior to transfusion, children should be evaluated 
Anemia, growth & development, skeletal changes, organomegaly (liver 
& spleen), facial changes, 
Laboratory work up48. 
Complete blood count, red blood cell indices, peripheral smear, liver 
function tests, molecular diagnostics, hepatitis serology, HIV screening, blood 
grouping & cross matching, dentition. 
Pre transfusion hemoglobin should be maintained between 9.5 to 
10gm/dl. Once in 2 to 5 weeks (moderate transfusion). Number of transfusion 
should be less than 200ml/kg) year. Super transfusion and hypertransfusion 
regimes maintaining pre transfusion Hb of more than 12gm 1dl and 10gm 1d1 
is not regularly practiced. Safe transfusion techniques should be followed. 
CHELATION THERAPY: 
The main motive of chelation therapy is to prevent tissue damage caused 
by transfusional hemosiderosis and iron overload because of thalassemia per 
say. i.e to increase the excretion of iron and prevent accumulation and toxicity. 
Indications for initiation of chelation therapy are8: 
 Blood transfusion of one year corresponds to iron overload  
 serum ferritin of 1000ng/ml  
 more than 2500 micro gram dry weight of liver iron concentration. 
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Currently three iron chelators are available: 
 Desferrioxamine ,deferasirox, deferiprone 
DESFERRIOXAMINE: 
It can be administered both subcutaneously as well by intravenous route. 
Dose : 20 – 50 mg / kg per day, given for five to seven days a week.  
Half life- < 30 minutes. 
Subcutaneous infusion has to be given slowly over 8 to 12 hours as a 10 
percent solution. Local skin reactions can be minimized by applying a local 
anesthetic prior to starting infusion and following the recommended strength 
and duration of infusion. 
Systemic side effects like high frequency hearing loss, cataracts, night 
blindness due to retinal damage, disproportionate truncal growth causing short 
stature are seen. 
Patients should be monitored once in a year for these side effects. 
Major draw back is poor compliance because of route of administration 
and side effects. Hence the newly available oral iron chelator is preferred. 
DEFERIPRONE: 
Its an oral iron chelating agent, available in India.  
One atom of iron is bound by three molecules of deferiprone and 
excreted in urine.  
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Dose : 25mg/kg three times a day. 
Half life: 3 hours. 
Very useful in decreasing cardiac toxicity due to iron.  
Side effects: agranulocytosis, neutropenia, arthropathy, gastrointestinal 
symptoms, zinc deficiency. Hence monitoring of weekly white blood cell count 
should be done as death is reported rarely. 
DEFERASIROX: 
Two molecules of this combine with one molecule of ferric iron to form 
a complex.  
Dose: 20-30mg/kg once a day orally in empty stomach. 
Half life -16 hours. 
Side effects: renal dysfunction , gastrointestinal disturbances, skin 
rashes elevated transaminases. 
HYDROXYUREA: 
This drug is used to increase the level of HbF which indirectly decreases 
the hemolysis. 
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STEM CELL TRANSPLANTATION:  
It is the definitive cure therapy for thalassemia patients. The option for 
stem cell transplant should be given to all patients who have a HLA matched 
sibling8,16. 
GENE THERAPY: Is under trail and hope fully it will be available in future8,16. 
PREVENTION OF COMPLICATIONS 
 By adequate regular transfusion to maintain adequate growth and 
prevent extramedullary erythopoeisis. 
 Iron chelation theraphy – to prevent end organ damage like liver, cardiac 
failure and endocrine disturbances. 
 .Prevention of infections transmitted by blood transfusion by effective 
screening promoting the quality of voluntary blood donators, 
leucodepleted packed red blood cells. 
 Treatment of cardiac complications is mainly by iron chelators. More 
than half the patients with failure are known to improve with parenteral 
desferrioxamine infusion and a combination therapy with deferiprone37, 
diuretics. Ionotropes and anticoagulants are also used. 
 Trials are on for treatment with sildenafil, inhaled nitric oxide, 
bosenatan and arginine for treatment of pulmonary hypertension in 
thalassemia patients. Eporostenol an antithrombotic agent has also been 
reported to be useful in treatment of PH in thalassemics  
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PREVENTION OF COMPLICATIONS by monitoring: 
Regular follow up of patients and monitoring complications related to 
blood transfusions, iron overload, other supportive measures like growth 
monitoring, assessment of liver functions and kidney functions by blood tests, 
endocrine complication like diabetes , short stature , hypothyroidism, 
hypoparathyroidism should be seen. Ophthalmological and auditory evaluation 
for chelation toxicity should be done in children of more than ten years of age. 
PREVENTION 
Pre natal diagnosis is essential for prevention as the prevalence of 
carriers for thalaseemia is 3 to 11 % in India47.  
Sardinia5 and Cyprus have programmes for increasing thalassemia 
awareness resulting in more number of people undergoing screening tests. 
Genetic counselling and prenatal testing in these countries showed a decline in 
thalassemia from 1 in 250 to 1 in 4000 births.  
Medical termination of pregnancy for thalassemia is permitted in Iran if 
conception is less than 16 weeks. 
Prenatal diagnosis can be done by the following methods34 
 Chorionic villous sampling(CVS) 
 Amniocentesis 
 Per cutaneous umbilical blood sampling(PUBS). 
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Chorionic villous sampling: 
It is performed at 10-12 weeks of pregnancy where adequate DNA is 
obtained by ultrasound guidance. Placental tissue sample is taken by a catheter 
that is placed trans cervically or trans abdominally and trophoblast cells are 
analysed.. Genetically abnormal fetus can be picked up at the earliest by CVS. 
Pregnancy loss rate is 0.5 to 1 percent when performed by skill full hands. 
Complications of performing CVS earlier are limb reduction defects of fetus 
and other abnormalities in oro mandibular development34,47. 
Amniocentesis : 
Amniotic fluid containing fetal cells is taken in second trimester through 
ultrasound guided images. Around 20 ml of amniotic fluid is removed for 
analysis which will be replaced by fetus in a day. α and β thalassemias can be 
detected by direct detection of a DNA mutation. Mutation is accomplished by 
allele specific oligonucleotide analysis. In α thalassemias, deletion of DNA can 
be seen as change in the DNA fragment size after a PCR. Incidence of fetal loss 
is 0.5 to 1 percent. Limb anomalies can also be seen34,47. 
Percutaneous umbilical blood sampling: (PUBS) 
It is a procedure performed from second trimester till term with 
ultrasound guidance. It not only provides access for in utero treatment but also 
diagnostic samples for hematological, cytogenetic, DNA and immunologis 
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studies is obtained. Risk of fetal loss: 1 to 2 percent. Complications- 5 percent 
chances of preterm delivery.  
Cordocentesis: 
About 2 to 3 ml of fetal blood is aspirated and analysed for globin 
chains by gel electrophoresis. An α/γ synthesis ratio more than 0.02 to 0.03 
suggests a normal fetus. Its is rarely practised . 
As prenatal testing is costly and an emotional burden to parents i. e 
losing a pregnancy if thalassemia is detected, it is better that pre marital testing 
and genetic and screening tests be done at school level. 
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REVIEW OF LITERATURE. 
A descriptive observational study was done by Samira Z Sazed etal, on 
56 patients of beta thalassemia major attending hematology opd at children 
university hospital, Al Minia University . Study duration was from February 
2009 to april 2011 at Egypt to detect early cardiac involvement in beta 
thalassemia patients.  
56 of thalassemia major patients who received blood transfusions ≥ 12 a 
year were part of research. Patients were divided based on the iron overload 
diagnosed by the serum ferritin values into three groups12. 
1. serum ferritin < 2500ng/ml- 21 patients. 
2. Serum ferritin 2500 -5000ng/ml -23 patients. 
3. serum ferritin > 5000 ng/ml 12 patients. 
These patients were evaluated clinically and investigated with serum 
ferritin, ecg and echocardiography. Corrected QT intervals and QT dispersion 
was seen in ecg. Systolic and diastolic functions of left atrium was assessed by 
echocardiography and tissue Doppler imaging. Results was groups 2 and 3 with 
serum ferritn values of more than 2500ng/ml and more than 5000ng/ml 
respectively had a significant increase in left ventricular septal and posterior 
wall thickness compared to group 1 with serum ferritin values less than 
2500ng/ml. 
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QTc and QTd was increased significantly in group with serum ferritin 
more than 5000ng/ml compared to the group with serum ferritin less than 
2500ng/ml. 
Groups 2 and 3 had significantly impaired emptying fraction and LV 
diastolic function compared to 1.Tissue Doppler imaging showed impaired LV 
systolic function in group 3 than group 1 with significant difference by 
standard echocardiography. Conclusion was increase in left ventricle septal and 
posterioir wall thickening was seen earliar to changes in ecg, left ventricular 
diastolic dysfunction and impairment of left atrium active emptying fraction is 
seen earlier than left ventricular diastolic dysfunction. 
Another study done by Noor Mohammad Noori etal at Iran for early 
diagnosis of cardiac dysfunction by a comparison of QT dispersion with left 
ventricular mass index in thalassemia major patients24. 
1. To compare the diagnostic value of corrected QT dispersion and QT 
dispersion with the left ventricular mass and left ventricular mass 
index. 
2. To determine the specificity and sensitivity of these in early detection 
of involvement of cardia in thalassemia major patients. 
It was a case controlled study done on 60 patients of thalassemia major 
patients older than 10 years of age and compared with healthy subjects who 
matched with sex and age. They observed that cases had a mean age of 16.08+_ 
2.8 years and controls had a mean age of 16.08+_3.01 years respectively.male : 
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female ratio was 33:27 in cases and 31:29 in controls.Case group had a greater 
mass index than the control group. 
Case group had a larger QTcd and QTd than the control group.  
The sensitivity and specificity was as follows 
 Sensitivity Specificity 
LV mass 88.3% 77.1% 
LV mass index 86.7% 80% 
QTcd 93.8% 80% 
QTd 91.7% 86.7% 
 
They concluded in the study that sensitivity and specificity of QTcd 
,QTd compared to LVmass was acceptable. In asymptomatic patients of 
thalassemia major standard ecg can be used as for early diagnosis of cardiac 
involvement24. 
A prospective study by Ameen Mosa etal done at department of 
cardiology23, Duhok University, Iraq on beta thalassemia intermedia patients 
showing the cardiac complications .It was done to correlate the clinical features 
of cardiac complications of thalassemia intermedia patients with 
echocardiograph. The standard echo of 2D, M mode was performed on 31 
females and 30 males to know the cardiac chamber dimensions. Tricuspid 
regurgitation velocity was recorded using continuous Doppler. Diastolic 
function of left ventricle was evaluated using pulsed Doppler of inflow of 
mitral valve. Patients were divided into three groups based on the tricuspid 
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regurgitant velocity to correlate echocardiographic and clinical findings. Mean 
age of patients was 19.6 years. They observed that the first group- tricuspid 
regurgitant velocity <2.5 m/sec was seen in 42 patients( 69%).Second group 
with tricuspid regurgitant velocity 2.5 to 2.9 m/sec was seen in 11 patients(18 
%).Third group with tricuspid regurgitant velocity > 3 m/ sec was seen in 8 
patients (13 %). Congestive cardiac failure was seen in 3 patients(4.9%).Group 
three patients were older and had more males with low hemoglobin and high 
ferritn values. Age at diagnosis and first blood transfusion was at a later age. 
Clinically they were symptomatic and had exertional dyspnea. 
Echocardiagraphy revealed increased right ventricular diameter and size of 
right atrium. They also had low ejection fraction relatively. 
Tricuspid regurgitant velocity was associated positively with age, 
pulmonary regurgitation and cardiac volumes when used as a continous 
predictor. Negative association was seen with ejection fraction. 
The conclusion was that echocardiography is a useful test for early 
evaluation of cardiac condition. It can reveal many abnormalities of cardiac 
complications in thalassemia intermedia patients. 
Thalassemia intermedia patients should be necessarily offered 
echocardiographic assessment early in life.In thalassemia intermedia patients 
echo derived complications of left and right side of heart are not uncommon. In 
this which was extended , it was further concluded that inTI, PH is the leading 
cause of heart failure23. 
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A study of echocardiographic parameters of left ventricle systolic and 
diastolic function in patients with β thala ssemia major was done by Asaad 
Abdullah Abbas etal at Ibn Albalady Hospital for Children and Maternity at 
Baghdad22. It was cross sectional descriptive study was done on a total of 427 
thalassemia major patients receiving regular blood transfusions and chelation. 
Objective was to assesss the left ventricular systolic and diastolic 
parameters in β- thalasemia major children and its relation to spleen status and 
ferritin level. It was a cross sectional descriptive study done on thalassemia 
major patients who were on regular blood transfusions and chelation. A gap of 
minimum of 48 hours was there between blood transfusions and analysis of 
cardia by echocardiography. procedure was done as per the guidelines of 
American Society of Echocardiography for paediatric patients. M –mode, 2D 
and Doppler echocardiography was averaged to 3 cardiac cycles 
The results wre that 
 Left atrium , aortic diameter , left ventricular posterior wall thickness, 
LA/AO ratio, interventricular thickness , LVEDd,LVEDs diameter 
was increased in thalassemia major patients. 
 thalassemic patients had higher stroke volume, MPI and L V mas 
index . fraction shortening and ejection fraction showed no changes. 
 thalasemia patients also had higher peak A, peak E and isovolumic 
relaxation time. But E deceleration time and E/A flow ratio showed 
no difference in comparison with the controls. 
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 i-mitral valve parameters by Doppler showe no effect in relation to 
serum ferritin level and spleen status. 
They concluded that patients of beta thalassemia have a systolic function 
that is good but diastolic function is decreased. There was no relation between 
the systolic and diastolic functions of LV and serum ferritn levels. 
In an observational study done done by Meloni A etal, 60 thalassemia 
major patients were included in the study. They reported the echocardiography 
findings in these patients11 
Echo was done to evaluate the association between tricuspid regurgitant 
velocities , serum ferritin , dyregulation of arginine and serological markers of 
hemolysis. They observed that low risk of pulmonary hypertension was found 
in well transfused thalassemia major patients than thalassemia intermadia 
patients. Vascular stressors was found in thalassemia major patients that 
increased the life time risk of pulmonary hypertension to levels that is higher 
than that of the general population. 
Their study supported the recommendations of yearly screening of 
thalassemia major patients by echocardiography. 
They conclude that patients with persistent TRV of more than 3m/s need 
cardiac catheterization.  
A study done by A. Azarkeivan etal, published in Medwell journals, 
2009,showed the involvement of cardia in transfusion dependant β thlassemia 
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major patients. It was done to study cardiac complications in transfusion 
dependant beta thalassemia patients56. 
It was a descriptive study done at Ali Asghar Childrens Hospital an 
Adult Thalassemia Clinic. Study sample-139 patients more than 7 years of age 
on regular blood transfusions and chelation therapy. History regarding duration 
of blood transfusion, age sex, respiratory complaints, signs of failure was 
asked. Physiscal examination was done. 
These patients were subjected to chest xray, Ecg, arterial blood gas 
analysis, and echocardiography.following observations was made. 
1. thalassemia major patients-104, thlassemia intermedia patients-35. 
Age  21.2±7.1years 
Serum ferritin 15,362±1609 ng/dl 
Ejection fraction 60.3± 9.7 % 
LVEDV 4.70±.6 mm3. 
Desferioxamine 52.1±.10.9 mg/kg 
2.  No correlation found between LVEDV and age and significant 
correlation was found between LVEDV and ejection fraction.  
They concluded that significant correlation was found between age of 
transfusion dependant thalassemia patients and cardiac failure. Well 
chelated patients can have alteration in cardiac functions. Regular follow 
up echocardiography is essential in thalassemia patients. Serum ferritin 
is not ideal for assessment of body iron store.  
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An study published by Sara Malik , on complications seen in beta 
thalassemia patients who are transfusion dependant shows that more 50 % of 
mortality in these patients is secondary to cardiac disorders1. 
Heart complications can manifest as cardiac failure, rhythm 
disturbances, hemosiderotic cardiomyopathy, pulmonaty hypertension, 
pericarditis, myocarditis. Reasons for cardiac decompensation are- iron 
overload, immunologic factors ( major histocompatibility antigens), genetic, 
chronic anaemia, infections. 
Endocrine complications like short stature , delayed puberty , gonadal 
dysfunction are also seen in these patients. Reasons implicated for dysfunction 
of multiple endocrine organs are: 
 chronic anemia 
 deficient micronutrients 
 low levels of IGF -1; IGFBP-3 
 deposition of iron in pancreas 
Metabolic complications: low levels of trace elements is seen 
Hepatic complications: manifests as hepatomegaly, increased liver 
enzymes, fibrosis. 
Hepatocellular carcinoma can complicate co existing infections of 
hepatitis B and C. 
  
 38 
Other complications like low IQ, infections, hypersplenism is also seen 
in chronically transfused patients.  
Conclusion was that prevention by antenatal testing , premarital 
screening and genetic counseling should be done. And stem cell transplantion 
is the definitive cure. 
In a study by Noor mohammad Noori etal, diagnostic value of Ecg in 
measuring the left ventricular mass index was compared with 
echocardiography. Study was performed on thalassemia major patients at a 
children hospital in Iran who were more than ten years of age24.  
82 patients of which 40 were women and 42 men were asymptomatic at 
the time of investigation. They finally concluded that echocardiography was 
more accurate in knowing the left ventricular mass index than 
electrocardiography.they also noted an increase in the LV mass and there was 
no correlation between QT changes in ecg and LV mass in echocardiography. 
K, Papadopoulou et al in their study done on 93 beta thlassemia major 
patients in the age group of 2.5 to 18 years found that the patients with good 
compliance to chelation therapy had lower incidence of overt heart disease 
compared to poor compliance patients. they also found that left ventricular end 
diastolic dimension , left ventricular mass and LV mass index was increased 
compared to normal controls of same age and gender and that these were the 
earlier signs of dilated cardiomyopathy on echocardiography26. 
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Cardiothoracic ratio was increased in 8 % and ecg abnormalities seen in 
12 5 of the patients, and only 9 % of them had abnormalities detected in 
echocardiography. 
In a study by Tanner etal it was found that combined chelation with oral 
deferiprone and subcutaneous deferoxamine improves myocardial function by 
decreasing cardiac iron load. They also observed that LV ejection improved 
along with myocardial function following combined chelation therapy31. 
In a study by Sylvia etal at Childrens Hospital Oakland Research 
Institute , California, 25 patients of thalassemia ( TM=18, TI=7 ), aged 10 years 
and above, 17 of them were found to have PH, of which 56%(n=10) of them 
were TM and 44%( n=7) were TI patients respectively. However all the TI 
patients had PH28. 
Mean hemoglobin level was 9.5 gm/dl, lower than the patients without 
PH. Mean serum ferritin was higher than the patients who did not have PH. 
Mean age was higher than those without PH. 
They concluded that mild to moderate pulmonary hypertension had high 
prevalence in well transfused TM and most importantly in TI patients. 
And platelet activation might have a role in development of PH in these 
patients. 
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AIM OF THE STUDY 
1. To study the cardiovascular complications in beta thalassemia 
major / intermedia patients aged 2 to 12 years on regular blood 
transfusions and  
2. To establish the significance of echocardiography in these 
patients. 
3. To study the clinical profile of beta thalassemia major/ intermedia 
patients coming to Institute of Child Health and Children 
Hospital, Chennai. 
  
 41 
OBJECTIVE 
 To evaluate β thalassemia patients of 2 to 12 years of age using 
echocardiography 
 To study the co relation between serum ferritin level and cardiac 
function through echocardiography in these patients. 
 To compare echocardiography findings in β thalassemia major 
and intermedia patients 
 To study the clinical profile of thalassemia major/ intermedia 
patients attending tertiary care centre at Institute of Child Health 
and Children, Chennai. 
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STUDY JUSTIFICATION 
1. Hemoglobin disorders are the cause for about 3.4% death in children 
younger than 5 years. 
2. Despite advances in therapeutic management of thalassemia resulting 
in remarkable improvement in survival of patient, heart disease 
remains the most common cause of moratlity and morbidity.  
3. Congestive cardiac failure and arrthymias are potentially lethal 
complications of increased iron load in thalassemia patients. 
4. In India, studies regarding regular screening of cardiac complications 
in first decade by echocardiography are minimal. 
5. Though cardiac MRI is gold standard in evaluating cardiac iron load, 
due to the disadvantages, (cost, time consuming, non availability in 
resource poor setting, claustrophobia, contraindications in patients on 
cardiac pace maker and metallic fragments and bodies). 
Echocardiography is widely used.  
6. Advantages of Echocardiography are it is cost effective, widely 
available, less time consuming, does not require anaesthesia, can be 
used as non invasive screening test in thalassemia patient. 
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METHODOLOGY 
Design of the study: Hospital based cross sectional study. 
Place: Institute of child health and children hospital. 
SAMPLE SPECIFICATIONS: 
Case definition: Cases of thalassemia major / intermedia confirmed clinically 
and by hemoglobin electrophoresis on regular blood 
transfusions. 
Inclusion criteria: 
1. Thalassemia major /intermedia patients in the age group of 2 to 12 
years. 
2. Who are receiving regular one or more blood transfusions per month for 
two or more years. 
3. Diagnosis confirmed as thalassemia major/ intermedia clinically or by 
hemoglobin electrophoresis. 
Exclusion criteria: 
1. Thalassemia patients with known cardiovascular complications or 
congenital heart diseases. 
2. Patients with terminal illness. 
3. Patients or parents not giving consent to participate in the study. 
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Sample size: 54  
CONFLICT OF INTEREST: nil 
FINANCIAL SUPPORT: nil  
Ethical Committee clearance was obtained from the institutional review 
board. 
MATERIALS AND METHODS 
SUBJECT SELECTION:  
Patients of thalassemia major and intermedia in the study age group on 
regular blood transfusion and chelation therapy attending tertiary care centre 
satisfying the inclusion and exclusion criteria were recruited into the study after 
getting informed parental consent. 
History and analysis of old records was done for the following- 
 Age at diagnosis 
 Consanguinity 
 Frequency of blood transfusions 
 Number of transfusions 
 Hemoglobin electrophoresis report- thalassemia major/ 
intermedia 
 Family history to know the number of affected/ normal/ carrier 
siblings 
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 Duration of chelation therapy 
 History suggestive of cardiac illness such as easy fatiguability, 
palpitations,hurried breathing 
 Whether patient is a known case of cardiac disease or not 
ANTHROPOMETRY: 
It included measurement of height , weight and body surface area of the 
subjects and plotted on standard charts and assigned Z scores. 
VITALS: 
Heart rate, respiratory rate and temperature was measured. Both systolic 
and diastolic blood pressure was measured. 
Signs of pallor, jaundice was seen. 
Systemic examination was done.  
Cardiovascular system-for evidence of murmurs, rhythm disturbances. 
Respiratory system-to rule infections of lung parenchyma. 
Abdomen for evidence of hepatomegaly and splenomegaly. 
INVESTIGATIONS: 
Complete blood count: for hemoglobin, total wbc count. Platelets 
estimated using autoanalysers. 
Chest xray was done to look for of evidence of cardiomegaly 
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Serum ferritin to know the iron load, using chemiluminescence 
technology. 
Ecg to know rhytm disturbances and Qtc interval 
Echocardiography: the following parameters was assessed -LVIDd, 
LVIDs, IVS thickness , posterior wall thickness to know LV mass. To evaluate 
cardiac function ejection fraction, fraction shortening, by trans thoracic 2D, M 
mode echocardiography. TR velocity and pulmonary pressure gradient for 
estimation of pulmonary hypertension by continuous wave Doppler.  
MATERIALS: 
Details of the patient – present age, sex, age at diagnosis. 
Type of thalassemia (major / intermedia)- clinical severity varies with 
the type of β- thalassemia. Patients of beta thalassemia major require frequent 
transfusions at 2 to 6 week intervals but those of thalasemia intermedia need 
less frequent transfusions. However patients who are transfusion dependant 
were included in the present study. 
Residence: to know the prevalence of the disease and geographical 
distribution 
Family history: To know consanguinity, sibling history (to know the 
number of affected/ deaths/ carriers/ normal children) 
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Duration of the disease and frequency of blood transfusions: to know the 
chronicity of disease and to estimate the severity of iron overload with 
transfusions, cardiac dysfunction, growth. 
Chelation therapy: whether patient was on oral chelation therapy/ not 
If yes, then the duration and dose of oral chelation therapy. In our hospital 
patients received deferasirox tablets ( dose 10 -30mg/ kg /day once a day in 
empty stomach) 
ANTHROPOMETRY: 
Height for age: Standing height of the child is measured using 
stadiometer where occiput, shoulders, buttocks , heels are touching against the 
vertical board. Head is positioned in Frankfurt plane. Height for age is plotted 
in the standard growth chart (WHO growth chart 2015). 
Weight for age: It is obtained by measuring weight in kilograms and 
plotted using WHO chart. 
Body surface area: weight in kilogram and height in cm plotted on body 
surface area nomogram 
Features of anemia like pallor, is seen . 
Vitals : 
Heart rate –tabulated as normal or tachycardia based on 
PALS(Paediatric Advanced Life Support) 
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Age : 2 years to 10 years- normal(60-140), > 10 years -60-100per 
minute. Tachycardia is more than the upper limit of normal for age. 
Respiratory rate-rate more than the upper limit of normal for the 
corresponding age was considered as tachypnoea.  
1 year to 3 years :24-40 per minute 
4 years to 5 years :22 to 34per minute 
6 years to 12 years:18 to 30 per minute.  
Temperature:measured in axilla: normal is 36.5ºC to 37.5 ºC. 
BLOOD PRESSURE: is measured using sphygmomanometer with age 
appropriate size cuff, patient in sitting position. An average of three readings of 
systolic and diastolic BP is plotted on NHBPEP (National High Blood Pressure 
Education Program , 2004) normogram. 
Blood pressure more than 95th percentile for age and gender is 
considered as hypertension. 
Complete blood count: to know the hemoglobin and indices prior to 
transfusion and echocardiography.  
Serum ferritin: sample for serum ferritin was collected during 
cannulation prior to blood transfusion .  
Hemoglobin electrophoresis: report was used to classify thalassemia into 
major and intermedia 
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Chest X ray: was done to look for evidence for cardiomegaly using 
cardiothoracic ratio for age 
Electrocardiogram: Standard 12 lead ECG was done at admission. Based 
on R/S ratio RVH is present when R/S ratio is increased and LVH when R/S 
ratio is decreased in these leads QT c interval was calculated using standard 
formula. Bazzet’s formula=QT/√ܴܴ݅݊ݐ݁ݎݒ݈ܽ. According to this normal QTc 
interval is 0.44 seconds in children 6 months and older. This can be increased 
in myocarditis and dilated and hypertrophic cardiomyopathies. 
Echocardiography: Echocardiography was performed on patients using a 
Philips Envisor ultrasound machine having a transducer of 3.5/5 and 2.5/5 
MHz. 2 D, M mode, and Doppler echocardiography was done as per the 
guidelines of American society of echocardiography. LV end diastolic 
diameter, LV end systolic diameter , systolic and diastolic interventricular 
septum diameter, LV posterior wall thickness in systole and diastole was 
calculated using M – mode echocardiography. Ejection fraction and fractional 
shortening was also calculated using the same. 
L V mass was calculated using the formula 0.8×1.04× ((LV end 
diastolic diameter+ Posterior wall thickness+ interventricular septum 
thickness)3_ (LV end diastolic diameter)3 )+0.6. and LV mass index was 
indexed to body surface area. Tricuspid regurgitant velocity was measured by 
pulsed Doppler. 
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Pulmonary hypertension was measured using tricuspid regurgitant jet 
velocity and modified Bernoulli equation (∆P=4V2). Pulmonary hypertension 
was diagnosed when the mean pulmonary artery pressure is >25 mm of 
Hg.Echocardiography was done on 54 patients in the age group of 2 to 12 years 
atleast 48 hours after the last transfusion, in a supine position .  
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STATISTICAL METHODS 
The history of patient, anthropometry, physical examination findings, 
laboratory investigations , echocardiography findings were collected from the 
children included in the study and recorded in data collection form. The data 
entered in excel sheet. Data analysis was done by using epidemiological 
information package in computer. Frequencies, means , percentage , standard 
deviations, fisher’s exact test, co-efficient of correction values and p value 
were calculated by using SPSS software frequencies. 
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OBSERVATION AND RESULTS 
Age wise distribution of cases 
Age (in years) No. of patients % 
2—6 34 63% 
7--12 20 37% 
Total 54 100% 
 
 
In the present study, there were 63% (n=34) in the age group 2 to 6 
years and 37% (n=20) were of age group 6 to 12 years. 
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Gender distribution of cases 
 No. of patients % 
Male 34 63 
Female 20 37 
 
 
 
In the present study, male patient were predominant with 63% (n=33) as 
compared to female patient 37% (n=20). 
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Geographical distributions of cases 
AREA No. of patients % 
Rural 31 57 
Urban 23 43 
Total 54 100 
 
 
 
In this study, children belonging to rural area accounted for 57% (n=31) 
which is predominant as compared to children from urban area 43% (n=23) 
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 55 
Type of Marriage 
Type of marriage No. of patients Percent 
Consanguineous 24 44 % 
Non consanguineous 30 56 % 
Total 54 100 % 
 
 
 
In the this study, 56% (n=30) were children born to parents with non 
consanguineous marriage and 44% (n=24) were born to consanguineous 
married couple 
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THALASSEMIA 
Hb electrophoresis No. of patients Percentage 
Intermediate 7 13% 
Major 47 87% 
Total 54 100% 
 
 
In this study, 87%(n=47) were patients with thalassemia major and 
13%(n=7) were patients of thalassemia intermedia. 
Frequency of transfusion 
Transfusion n Percent 
Monthly 47 87% 
2 months 5 9% 
3 months 2 3% 
Total 54 100 % 
In our study, 85 % (n=46) received transfusion monthly, while 9% (n=5) 
received blood transfusion once in 2 months and 6% (n=3) received transfusion 
once in three months  
47
7
THALASSEMIA
MAJOR INTERMEDIA
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Family history 
Sibling n Percentage 
1 affected 4 7% 
1 dead 3 6% 
2 dead 3 6% 
1 normal 27 50% 
2 normal 4 7% 
Nil 13 24% 
Total 54 100% 
 
 
 
In this study, 57% had normal/carrier siblings and 12% had sibling death 
in family while one child of TI was on blood transfusion. 
  
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
1 affected 1 dead 2 dead 1 normal 2 normal nil
7% 6% 6%
50%
7%
24%
Status of Sibling
 58 
Height 
 
In this study, there were 16 patients who had height less than 3 SD , and 
38 patients height was more than 3 SD .  
Weight 
 
In this study, 33%(n=18) had weight < third centile, 19 % (n=10) had 
weight <10 centile.  
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Heart Rate 
 
 
 
In this study, 54% (n=29) patient had tachycardia at admission and 46% 
(n=25) had normal heart rate at admission. 
  
46%
54%
Proportion of HR
Normal
Tachycardia
HR N Percentage 
Normal 25 46% 
Tachycardia 29 54% 
Total 54 100% 
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ECG findings 
ECG No. of patients Percentage 
Normal 35 65 
Abnormal 19 35 
Total  54 100 
 
 
 
In this study, 65% (n=35) had normal ecg and abnormal ecg was seen in 
35 % (n=19) cases. 
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Serum Ferritin Level 
SERUM 
FERRITIN (ng/dl) No of patients Percentage 
<1000 13 24 % 
>1000 41 76 % 
Total 54 100 
 
In this study, 24% (n=13) had normal ferritin level while 76% (n=41) 
cases had serum ferritin level more than 1000 ng/dl 
Consanguinity 
Serum Ferritin 
(ng/dl) Consanguinity Non consanguinous Total 
<1000 4 (17%) 9 (30%) 13 (24%) 
>=1000 20 (83%) 21 (70%) 41 (76%) 
Total 24 (100%) 30 (100%) 54 (100%) 
χ2 = 0.67, degree of freedom(df)=1, p=0.413(NS) 
In the present study,there is no statistically significant association 
between serum ferritin level and consanguinity .  
 Residence   
Serum 
Ferritin(ng/dl) Rural Urban Total 
<1000 9 (29%) 4 (17%) 13 (24%) 
>=1000 22 (71%) 19 (83%) 41 (76%) 
Total 31 (100%) 23 (100%) 54 (100%) 
χ2 =0.446, degree of freedom(df)=1, p=0.504(NS) 
In the present study,there is no statistically significant association 
between serum ferritin level and geographical distribution. 
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Frequency of transfusion with S. ferritin 
 Frequency of transfusion 
Serum Ferritin 
(ng/dl) 1 2 3 Total 
<1000 9 (20%) 2 (40%) 2 (67%) 13 (24%) 
>=1000 37 (80%) 3 (60%) 1 (33%) 41 (76%) 
Total 46 (100%) 5 (100%) 3 (100%) 54 (100%) 
χ2 = 4.2, degree of freedom(df)=2, p=0.088(NS) 
 
 
 
 
■ Monthly ■ Once in 2 Months  ■ Once in 3 Months 
In the present study, there is no statistically significant association 
between serum ferritin level and frequency of transfusions .it means that serum 
ferritin level is not a good indicator of chronicity of blood transfusions. 
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In the present study, low platelet counts had negative correlation with 
increase in spleen size. 
Electrocardiography 
 RVH 
Serum Ferriti 
 (ng/dl) + NIL Total 
>=1000 
3 35 38 
75.00% 81.40% 80.90% 
<1000 
1 8 9 
25.00% 18.60% 19.10% 
Total 
4 43 47 
100.00% 100.00% 100.00% 
Pearson Chi-Square  p value 0.756 (NS) 
 
In our study, RVH was seen in total of 8.5% (n=4) patient with 
thalassemia major. Among these serum ferritin level was high in 75% (n=3) 
and normal in 25%. Serum ferritin level had no association with RVH as p 
value not statistically significant.( p value 0.756)  
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  LVH 
Serum Ferritin 
(ng/dl) + NIL Total 
>=1000 
16 22 38 
93.80% 73.30% 80.90% 
<1000 
1 8 9 
6.20% 26.70% 19.10% 
Total 
17 30 47 
100.00% 100.00% 100.00% 
Pearson Chi-Square P value=0.217( NS) 
In this study, 36% (n=36.1) 17 patient of total 47 thalassemia patient had 
LVH in ECG. Out of 17 patient 93.8 %( n=16) had serum ferritin level more 
than 1000ng/dl. Serum ferritin level had no association with LVH as p value 
not statistically significant. (p value=0.217) 
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Echocardiogram 
 
 
In this study echo was normal in 33 % and abnormal echo findings was 
seen in 67% of patient. 
 
In this study, 63 % of patient showed increased LV mass/m2 in echo and 
37 % who had normal LV mass/m2 
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Correlation of Serum Ferritin with LV mass/m2  
Serum Ferritin (ng/dl) LV mass/m2 
Sample size (N) 54 
Pearson Correlation r 0.064 
p value 0.645 
Interpretation very weak positive correlation 
 
 
 
In this study, it is found that there is poor positive correlation of LV 
mass with the serum ferritin level. 
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Correlation of Age with LV mass/m2  
 
 
In the present study it was found that there is a positive correlation, r = 
0.28 . 
Age (in years) LV mass m2 
Sample size (N) 54 
Pearson Correlation r 0.282 
p value 0.041* 
Interpretation Poor positive Significant correlation 
 
In this study, it is found that there is poor positive correlation of LV 
mass/m2 with the age and p value was significant less than 0.041. 
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Ejection fraction 
 EJECTION 
FRACTION 
(Normal- 56% 
TO78%) 
No.of 
patients Minimum Maximum Mean Std. Error 
Std. 
Deviation 
54 55 82 69.96 0.767 5.637 
 
The mean Ejection fraction in our patients was 69.96% 
Tr Velocity 
Tr velocity EF LV mass/m2 
N 54 54 
Pearson Correlation -0.10 0.258 
p value 0.477 0.06 
Interpretation Weak negative correlation 
Poor positive 
correlation 
 
In this study , it seen that there poor positive correlation between LV 
mass and TRV. There is poor negative correlation between EF and TRV. It 
indicates that right and left ventricular dysfunction can occur independently. 
Serum Ferritin / Echo Findings 
  Serum ferritin (ng/dl) 
LV mass/m2 >=1000 <1000 Total 
INCREASED 27 3 30 71.10% 33.30% 63.80% 
NORMAL 11 6 17 28.90% 66.70% 36.20% 
Total 38 9 47 100.00% 100.00% 100.00% 
Pearson Chi-Square p value 0.034 (significant) 
In our study, 38 thalassemia major patients serum ferritin level was 
more than 1000ng/dl. In these cases LV mass/m2 was increased in 71.1 % and 
had 28.9 % cases had normal LV mass/m2 inspite of increased serum ferritin 
level. 3 patient with thalassemia major who had serum ferritin level below 
1000ng/dl had increased LV mass. This was statistically significant. 
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  Echocardiogram 
LV mass Abnormal Normal Total 
INCREASED 
29 1 30 
90.60% 6.70% 63.80% 
NORMAL 
3 14 17 
9.40% 93.30% 36.20% 
Total 
32 15 47 
100.00% 100.00% 100.00% 
Continuity Correction Chi square value p value 0.0001(highly significant) 
 
In our study, out of 47 thalassemia major patient 32 patient had 
abnormal echo findings which was statistically significant. 
Pulmanary Hyper tension 
 
 
In this study, pulmonary hypertension was seen in 24 % of patient and 
76% did not show evidence of pulmomary hypertension in echo. 
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Relation of Age at Diagnosis and Pulmonary Hypertension 
  Pulmonary hypertension 
Age at diagnosis Mild Normal Total 
<=6 months 4 (31%) 24 (59%) 28 (52%) 
7--12 months 4 (31%) 14 (34%) 18 (33%) 
> 1 year 5 (38%) 3 (7%) 8 (15%) 
Total 13 (100%) 41(100%) 54 (100%) 
*Significant at P<0.05 
χ2 = 7.964, degree of freedom(df)=2, p=0.019 (Significant) 
 
In the present study, the incidence of pulmonary hypertension showed 
statistically significant association with the age of diagnosis of thalassemia (p 
value = 0.019) 
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Pulmonary hypertension with Consanguinity  
  Pulmonary hypertension 
Consanguineous Mild Normal Total 
cm 6 (46%) 18 (44%) 24 (44%) 
ncm 7 (54%) 23 (56%) 30 (56%) 
Total 13 (100%) 41 (100%) 54 (100%) 
 
χ2 = 0.081, degree of freedom(df)=1, p=0.887 (NS) 
 
 
In this study, incidence of pulmonary hyptertension did not show any 
statistically significant association with the type of marriage. (p value =0.887) 
 
  
0%
10%
20%
30%
40%
50%
60%
cm ncm
46%
54%
44%
56%
Mild
Normal
 72 
Pulmonary Hypertension with Residence 
  Pulmonary Hypertension 
Residence Mild Normal Total 
Rural 6 (46%) 25 (61%) 31 (57%) 
Urban 7 (54%) 16 (39%) 23 (43%) 
Total 13 (100%) 41(100%) 54 (100%) 
χ2 = 0.081, degree of freedom(df)=1, p=0.535 (NS) 
 
 
In this study, incidence of pulmonary hypertension did not show any 
statistically significant association with the area of residence (p value =0.535) 
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Pulmonary hypertension with Gender 
  Pulmonary hypertension 
Gender Mild Normal Total 
Male 6 (46%) 28 (68%) 34 (63%) 
Female 7 (54%) 13 (32%) 20 (37%) 
Total 13 (100%) 41 (100%) 54 (100%) 
χ2 = 1.234, degree of freedom(df)=1, p=0.267 (NS) 
 
 
 
In this study, incidence of pulmonary hypertension did not show any 
statistically significant association with the sex of patient (p value =0.267) 
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Right Heart Functions with Serum Ferritin 
  Pulmonary hypertension 
Serum Ferritin (ng/dl) Mild Normal Total 
>=1000 10 28 38 100.00% 74.30% 80.90% 
<1000 0 9 9 0.00% 25.70% 19.10% 
Total 10 35 47 100.00% 100.00% 100.00% 
Pearson Chi-Square P value=0.148( NS) 
In this study, 21.2%(n=10) thalassemia major cases had pulmonary 
hypertension . All these patients had serum ferritin level more than 1000 ng/dl. 
Pulmonary hypertension and serum ferritin level have no association as p value 
is 0.148. 
 Tricuspid regurgitation Serum Ferritin 
(ng/dl) Mild Normal Trivial Total 
>=1000 10 17 11 38 90.90% 66.70% 78.60% 80.90% 
<1000 1 5 3 9 9.10% 33.30% 21.40% 19.10% 
Total 11 22 14 47 100.00% 100.00% 100.00% 100.00% 
Pearson Chi-Square P value=0.623(NS) 
In this study, out of total 47 thalassemia major patient 22 patient did not 
have tricuspid regurgitation. Serum ferritin level did not show any association 
with trisupid regurgitation as p value 0.623. 
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Thalassemia Intermedia (7 Patients) 
 
 
In the graph we can see that LVmass is increased in 71% (n=5) of 
thalassemia intermedia patients and 57% (n=4) had pulmonary hypertension. 
Also serum Ferritin was increased in 57% (n=4) patients ' 
Chi-square test is not used as the sample size was small. 
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SENSITIVITY ANALYSIS 
 ECG 
Echo Abnormal (+ve) Normal (-ve) Total 
Abnormal (+ve) 17 19 36 
Normal (-ve) 2 16 18 
Total 19 35 54 
 
Parameter Estimate Lower - Upper 95% CIs 
Sensitivity 89.47% (68.61, 97.06¹ ) 
Specificity 45.71% (30.47, 61.81¹ ) 
Positive Predictive Value 47.22% (31.99, 62.99¹ ) 
Negative Predictive 
Value 88.89% (67.2, 96.9¹ ) 
Diagnostic Accuracy 61.11% (47.79, 72.96¹ ) 
1 Wilson score method 
The sensitivity of echo in comparison with ecg in detection of any 
cardiac complication in thalassemia patient on chronic blood transfusion was 
89.47 % and specificity was 45.71% .The negative predictive value of echo is 
88.89 % (CI 95%) 
This can prove that 2 D echocardiography is more sensitive and as the 
negative predictive value is high. We can exclude any cardiovascular 
complication arising from chronic blood transfusion using 2 D 
echocardiography as initial screening tool. 
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Pictures of Echocardiography in Thalassemia Patients 
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DISCUSSION 
This study was conducted at Institute of Child Health and Hospital for 
Children, Chennai, from June 2015 to October 2015. 
We included 54 patients of β thalassemia who were transfusion 
dependant, to study the significance of echocardiography in them. Children 
more than 2 years of age and less than 12 years were part of the study. Children 
who had a congenital heart disease and those with the terminal illness were 
excluded from the study. 
Majority of the studies on cardiovascular complications done in the 
Mediterranian region and the South East Asia were in the age group who are 
more than ten years. In our study, all the patients were less than twelve years of 
age. 63%(n=34) were less than 6 years and 37%(n=20) between 6 and 12 years. 
In studies by Samira Z sayed et al, Noor mohammad Noori et al patients 
were more than ten years of age and A, Azarkeivan etal had patients more than 
seven years of age. It was seen in these studies that cardiac complications occur 
early inspite of regular blood transfusions and in well chelated patients. 
Gender Present study Samira Z Sayed et al Ameen mosa et al 
Male 63% 64% 49% 
Female 37% 36 % 51% 
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In the present study 63% (n=34) of the patients were males and 37% 
(n=20) females respectively. There are other studies done by Samira Z Syed 
etal (male -64%. Females-36%) and Ameen mosa etal (male-49% , females-
51%) where similar male preponderance was seen. Though the probability of 
the child inheriting the disease(autosomal recessive disorder) does not show 
sex predilection, it is seen more commonly in boys in few of the studies. 
In our study, 44 % (n=24) were born to consanguineous parents and 
56%(n=30) of them to non consanguineous parents. It implies that the parents 
of the proband are heterozygous and obligate carriers reflecting the high 
frequency of carriers in the population. It can be due to de novo mutations also. 
It is important as the relatives of carriers should also be screened and 
genetic counseling and premarital testing can prevent these births. 
A similar study by Samira Zyed et al in showed that around 32 % of the 
thalassemia patients were from consanguineous marriage , and 67.8 % were 
from non consanguineous marriage, where the prevalence is high. 
 Out of the 54 patients, 47 of them had thalassemia major and the remaining 
intermedia confirmed by hemoglobin electrophoresis. 
Age at 
diagnosis 
Present 
study Samira Z Sayed et al Ameen mosa et al 
Minimum age 
at diagnosis  3 months 6 months 6 months 
Mean 9.4 months 8- 9 months  6-9 months 
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The minimum age at diagnosis of thalassemia in our study was 3 
months, in comparison to 6 months in Samira Zyed etal and Ameen mosa et al 
study. As most of the affected thalassemia children present in infancy at around 
six months of age,this finding is significant as these children were screened for 
thalassemia after the death of their elder siblings.However the mean age of 
diagnosis 9.4 month as seen in the other studies 
Sibling history in our study showed that 57% (n=27) had an 
asymptomatic carrier/ normal child in the family. Whereas 24% (n=13) of the 
thalassemia patients in our study were being reared as a single child because 
the other pregnancy was terminated due to antenatal screening being positive . 
19 % (n=10) of these patients had a sibling who was affected with TM, 
of which only 7%(n=4) were alive, on transfusions, but 12%(n=6) had lost their 
brother or sister due to the disease or its complications .  
Geographical Area Present study Samira Z Sayed et al 
Urban 57 % 29% 
Rural  43% 71% 
 
In the present study 57% (n=) of the patients were from urban set up and 
43%(n=) from rural area. However this is not of significance as both the groups 
were on regular transfusions. 
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Frequency of transfusion: 
In our study 85% (n=47) of patients of thalassemia major were on 
regular blood transfusions once a month. 9% (n=5) of patients of TI were on 
blood transfusions once in two months and the remaining 6%( n= 2) patients 
once in 3 months respectively.  
Weight in kg Present study Samira Z Sayed et al 
< 5 percentile 33%(n=18) 35.7% 
5-95 centile 19%(n=10) 64.3% 
Mean weight 15.98 23 
 
In this study, 33% of the thalassemia patients had weight < third centile, 
i.e these patients were under weight and one third of the patients were 
malnourished. Similarly 30% of these patients, also had short stature. 
54% (n=29) of our patients had tachycardia and 46 % (n=25) had normal 
heart rate for the age. This is secondary to anemia, mean hemoglobin in these 
patients was 7.34gm/dl 
Mean EF was 70% and fraction shortening was 39.54.mean LVMI in 
these patients was 79.63 gm/m2. 
Similar results was seen in study by Samira Z etal, Noor Mohammad 
Noorietal and others. Chronic anemia causes increase in volume overload and 
heart rate. 
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Patients of thalassemia have a heart rate that is higher than the normal 
people for the corresponding age. 
All 54(100%) patients in our study had systolic and diastolic blood 
pressure less than the 95th centile when plotted on NHBPEP charts for their 
corresponding age and sex. Systemic blood pressure is well maintained in these 
patients. Study by Sara and S Dru Foote al observed that even patients with 
pulmonary hypertension had normal systemic blood pressure. 
Hemoglobin at admission  
Hb ( gm%) Present study Mosa et al 
Mean Hb 7.33 9 
Low Hb 6 7.9 
 
Mean hemoglobin values in our study was 7.33gm/dl. Low hemoglobin 
values may be the cause for pulmonary hypertension in these patients. Chronic 
anemia can cause growth retardation also. In a study by Mosa etal and Sara et 
al mean hemoglobin was 9gm/dl. 
Serum ferritin level 
 Present study Samira Z Sayed et al 
< 1000 ng/dl 24 % - 
>1000ng/dl 76% 100% 
  
In our study patients were further classified based on the serum ferritin 
value into those who had values more than 1000ng/ml and the ones with less 
than 1000ng/ml to know the extent of iron overload. Inspite of being on oral 
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chelators three fourth of the study population had serum ferritin more than 
1000ng/ml and only 24%(n=13) had values less than 1000ng/ml. 
Patient with least value of 215ng/ml had TI, on transfusions once in 
three months. 4 out of 7 of TI patients had ferritin lower than 1000ng/ml and 3 
of them higher. Frequency of blood transfusions in TI patients is less than TM 
patients. 
Patients with low values of ferritin had an average of total of 30 
transfusions.  
Serum ferritin values were compared with the chest xray, ecg and 
echocardiography findings to know the relation between cardiac function and 
iron overload. 
Of the 47 TM patients , 19%(n=9) , had serum ferritin values lower than 
1000 ng/ml whereas 80.90%(n=38) had serum ferritin values more than 
1000ng/ml. Out of the 38 patients with high ferritin values only 75% of them 
had RVH on ecg. Statistically no association was found with serum ferritin and 
ecg finding of RVH as p value was 0.756. Similarly serum ferritin had no 
association with LVH in ecg. But it was observed that 93% out of 38 patients 
of TM had LVH in ecg. 
In our study , 35 patients out of 54 had cardiomegaly on chest x ray, but 
only 77%(n=27) of these patients had high serum ferritin values which means 
that cardiomegaly in these patients can be due to chronic anemia and volume 
overload rather than iron overload alone. Qtc interval was in the normal range 
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in all patients. Electrocardiography did not show arrhythmias. Unlike the study 
by Samira et al where QTc and QTd was increased significantly in patients 
with serum ferritin level more than 5000ng/ml. 
Echocardiography showed that 10 out of 47 patients of TM had mild 
pulmonary hypertension and all these 10patients (100%) had serum ferritin 
more than 1000ng/ml. 
In our study, 38 out of 47 patients of TM had serum ferritin values more 
than 1000ng/ml and 71.10% (n=27) had increased LVmass. However serum 
ferritin had poor positive correlation with LV mass and pulmonary 
hypertension, hence it cannot be used as single marker for cardiac iron load in 
transfusion dependant thalassemia patients.  
Ejection fraction: it was found to be mildly elevated than the normal 
values for age. 
 Present study Samira Zet al Mosa et al A Azar et al  
Mean 69.96% 66.28% 65% 60 % 
Range  55% to 82% 62.3%to 70.12% 56-65 % 60.3±9.7% 
 
LV mass 
LV mass and LV mass index was increased in 63% (n=34) of the total 
patients i.e these children had LV mass and LVMI more than 95th centile for 
the corresponding age and sex in normal children. And 37%(n=20) had less 
than 95th centile for the corresponding age and sex when plotted on the age 
specific reference intervals for indexed left ventricular mass in children. 
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Similar findings were observed in other studies done by two separate studies by 
Noor mohammad et al. LVmass and LV mass index was seen increased in 
these studies done by Assad Abdullah Abbas etal, Ameen Mosa et al and 
Samira Z Sayed etal. 
Chronic anemia, tissue hypoxia and iron overload are some of the causes 
of increase in LVmass and LVmass index thalassemia. 
Increase in LV mass and LV mass index in thalassemia is multifactorial. 
It is due to chronic anemia, tissue hypoxia and iron overload.  
The dimensions used for calculating the LV mass like LVIDd, LVIDs, 
interventricular septal thickness and posterior wall thickness of ventricular wall 
was also observed to be increased in these patients above the average normal 
levels. 
Similar observations were seen in study by Ameenmosa et al, Samira Z 
Sayed et al. 
Pulmonary hypertension was seen in 24% of 54 patients in our 
study.76.9% (n=10) of these patients were of TM and 23% (n=3) were of TI 
respectively. However p value was not significant. But 42% of TI patients and 
21 % of TM patients had pulmonary hypertension. This shows that incidence of 
PH is more in TI than TM. Sylvia28 et al also observed in their study that high 
prevalence of pulmonary hypertension is seen in well transfused TM patients 
and most importantly in TI patients 
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8(62%) out of 13 children with pulmonary hypertension were diagnosed 
to have thalassemia in their infancy. 41 children did not have pulmonary 
hypertension. This was statistically significant as p value was 0.019.  
This implies that incidence of thalassemia intermedia is high as the age 
advances. However it had no association with consanguinity, geographical 
distribution, or sex of the patient. 
Mean hemoglobin in patients with pulmonary hypertension was 
7.4%and the mean age in these children was 5.38 years. 
In a study by Meloni etal it was seen that low risk of pulmonary 
hypertension was found in well transfused thalassemia major patients than 
thalassemia intermedia. 
Sylvia etal at Childrens Hospital Oakland Research Institute, California, 
also had high prevalence of PH in TI and in well transfused TM patients. These 
patients also had low hemoglobin and high serum ferritin levels than those who 
did not have pulmonary hypertension28. 
The sensitivity and specificity of echocardiography on thalassemia 
patients in our study when compared to ecg was found to be 89.47% and 
specificity was 45.7%. Negative predictive value was 89%.  
As Echocardigraphy findings was not compared with MRI, the efficacy 
of this procedure in confirming cardiac iron load is less. And hence T2* MRI is 
the gold standard in diagnosis of cardiac iron deposition. Further pulmonary 
hypertension should also be confirmed by cardiac catheterisation. 
Serum ferritin is not an indicator of cardiac iron overload. 
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Hence echocardiography combined with electrocardiogram can be used 
for regular periodic follow-up. Complications can be prevented in early in 
asymptomatic children. 
Even though mortality secondary to cardiac complications is seen in 
second decade, the pathologic changes occur in first decade only. This should 
be diagnosed early by easily available, affordable, non invasive technique like 
echocardiography. 
Echocardiography combined with electrocardiogram should be used for 
regular periodic monitoring of transfusion dependent thalassemia patients. 
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CONCLUSIONS 
 Cardiac complications can occur in first decade also secondary to chronic 
anemias and iron overload. 
 24 % of our thalassemia major patients have pulmonary hypertension. 
 63 % of our thalassemia patients had increased LV mass which was > 98 
percent of the age matched reference values. 
 Cardiac arrhythmias considered as the most common cause of death in 
thalassemia patients is not found in our patients. (< 12 years). 
 Serum ferritin value did not correlate with the cardiac abnormality found 
in echocardiography, hence Cardiac M RI which is considered as gold 
standard should be used.  
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LIMITATIONS 
 Being an institutional based study the findings cannot be projected at a 
community level. 
 Small sample size 
 All parameters of cardia have to be evaluated in echocardiography and 
compared with MRI and normal controls.  
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RECOMMENDATIONS 
 Echocardiography can be used for screening of cardiac complications in 
children less than ten years of age and followed up periodically. 
 As serum ferritin does not correlate with the cardiac iron overload and 
dysfunction, T 2 MRI which is the gold standard should be used.. 
 Importance of early involvement of cardia in thalassemia patients should 
be conveyed to all treating paediatricians.  
 Combination chelation therapy can be used  in patients with cardiac 
toxicity secondary to iron overload 
 In addition to prenatal diagnosis for thalassemia , pre marital screening 
should be offered at the community level. 
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ABBREVIATIONS 
RDW - Red Cell Distribution Width  
CVS - Chorionic Villous Sampling. 
PUBS - Percutaneous Umbilical Cord Blood 
Sampling 
TM - Thalassemia Major 
TI - Thalassemia Intermedia 
DNA - Deoxy Ribonucleic Acid 
ECG - Electrocardiogram 
PH - Pulmonary Hypertension 
Hb - Hemoglobin 
m RNA - Messenger Ribose Nuceic Acid. 
LV Mass - Left Ventricular Mass 
BP - Blood Pressure 
IVS - Inter Ventricular Septum 
PWT - Posterior Wall Thickness 
 
  
 101 
 
  
 102 
ANNEXURES 
INFORMATION SHEET 
Place of study: INSTITUTE OF CHILD HEALTH AND HOSPITAL FOR CHILDREN, 
GENERAL OPD 
Name of Investigator :  DR. USHA B K 
Name of Participant    age:   sex:  
Hospital No:        
Study title :  Study of Echocardiography in thalassemia( major/ intermedia) patients at tertiary 
care centre , ICH&HC , Chennai. 
 We are conducting a study of echocardiography in thalassemia(major/intermedia) 
patients at tertiary care centre, ICH & HC, Chennai. 
 Thalassemia  is an inherited hemoglobin disorder caused by impaired synthesis of the 
beta –globin chain and resulting in hemolytic anemia. 
 Depending on clinical severity , two forms thalassemia major and intermedia are 
defined. Cardiac complications are a main feature of the clinical spectrum of beta 
thalassemia. Despite adequate iron chelation , myocardial dysfunction is due to iron 
deposition, fibrosis, and chronic anaemia.  
 We are conducting a study in ICH & HC regarding study of echocardiography in 
thalassemia (major/ intermedia) patients in tertiary care centre ICH&HC, Chennai. 
We request you to participate in the study 
 The purpose of this study is to compare rapid screening tests with gold standard urine 
culture test for diagnosing urinary tract infection. 
 The privacy of the patients in the research will be maintained throughout the study. In 
the event of any publication or presentation resulting from the research, no personally 
identifiable information will be shared. 
 Taking part in this study is voluntary. You are free to decide whether to participate in 
this study or to withdraw at any time; your decision will not result in any loss of 
benefits to which you are otherwise entitled. 
 The results of the special study may be intimated to you at the end of the study period 
or during the study if anything is found abnormal which may aid in the management 
or treatment. 
 
Signature of investigator                                                                        Signature of participant 
Date:  
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INFORMED CONSENT FORM 
Study place: INSTITUTE OF CHILD HEALTH AND HOSPITAL FOR CHILDREN 
Title of the study: Study of Echocardiography  in  thalassemia (major/intermedia) 
patients at tertiary care centre,ICH&HC,Chennai. 
Name of the investigator  :  DR. USHA B K      
Name of the Participant:  Age:   Sex: 
Hospital number:    
1. I have read and understood this consent form and the information provided to 
me regarding the participation in the study.  
2. I have had the consent document explained to me.  
3. I have been explained about the nature of the study.  
4. I have been explained about my rights and responsibilities by the investigator.  
5. I have informed the investigator of all the treatments I am taking or have taken 
in the past including any native (alternative) treatment.  
6. I have been advised about the risks associated with my participation in this 
study.* 
7. I agree to cooperate with the investigator and I will inform him/her 
immediately if I suffer  
unusual symptoms. * 
8. I have not participated in any research study in the past. 
9. I am aware of the fact that I can opt out of the study at any time without 
having to give any reason and this will not affect my future treatment in this 
hospital. * 
10. I am also aware that the investigator may terminate my participation in the 
study at any time, for any reason, without my consent. * 
11. I hereby give permission to the investigators to release the information 
obtained from me as result of participation in this study to the sponsors, 
regulatory authorities, Govt. agencies, and IEC. I understand that they are 
publicly presented.  
12. I  understand that  my  identity will be kept confidential if my data are publicly 
presented  
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13. I have had my questions answered to my satisfaction.  
14. I have decided to be in the research study.  
I am aware that if I have any question during this study, I should contact the 
investigator. By signing  
This consent form I attest that the information given in this document has been 
clearly explained to me and understood by me, I will be given a copy of this consent 
document. For adult participants:  
 
Name and signature / thumb impression of the participant /parents/guardian  
Name _________________________ Signature_________________ 
Date________________  
 
 
Name and Signature of impartial witness:  
Name _________________________ Signature_________________ 
Date________________ 
 
 
Name and Signature of the investigator or his representative obtaining consent:  
Name _________________________ Signature_________________ 
Date________________  
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PROFORMA 
STUDY OF SIGNIFICANCE OF ECHOCARDIOGRAPHY IN 
THALASSEMIA  MAJOR/INTERMEDIA PATIENTS  ATTENDING A 
TERTIARY CARE CENTRE, ICH, CHENNAI. 
 
Serial Number:                                                      Ip No:                                     Date: 
1.Name:                                                2.     Age:                              3.  Sex: 
4. Residence: 
5. Socioeconomic Status:  (Modified Kuppuswamy Classf) 
6. Consanguinity: 
7.COMPLAINTS: 
  
8.PAST HISTORY: 
o Number of previous transfusions 
o On chelation therapy: yes/no 
9.FAMILY HISTORY: 
 
 
 
 
ANTHROPOMETRY: 
10. Weight:  Expected Weight:   Centile 
11. Height:             Expected Weight:   Centile:  
  
12. Body surface area:  
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GENERAL EXAMINATION 
13. Pallor   14. icterus / lymphadenopathy  
 
 
VITAL SIGNS 
15. Pulse rate                                    16. Respiratory rate 
17. Blood pressure                            18. Temperature 
SYSTEMIC EXAMINATION: 
19. Cardiovascular system: 
20. Abdomen: liver 
                       spleen 
21. Respiratory system: 
22. Central Nervous system: 
23. CBC:   HB:    PCV:   TC:  DC:  
             MCV:    MCH:   MCHC: RDW: 
  PLATELETS: 
24. HB ELECTROPHORESIS: 
 
25: SERUM FERRITIN: 
26. CHEST- XRAY: 
27. ECG: 
 
27. ECHO: 
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MASTER CHART 
 
  
name age sex ip no residence ses consanguinous age at diagnosis frequency chelation sibling weight < 3 PERCTILE
ashika 3 female 877016 rural low ncm 14 mon monthly yes 1 normal 14 N
swetha 11 female 877023 rural low cm 5 mon monthly yes 1 normal 22 LESS
vishwa 6 male 875387 rural low ncm 6 mon monthly yes nil 15 LESS
meenatchi 3.6 female 877342 rural low ncm 5 mon monthly yes 2 normal 15 N
yogeshwari 5 female 866447 urban low cm 11 mon monthly yes 1 normal 15 N
dhanush 9 male 862492 urban low ncm 5 mon monthly yes 1 normal 24 n
isha  9 female 862497 urban low ncm 7 month monthly yes 2 normal 23 n
sabarivasan 5 male 876510 rural low cm 5 months monthly yes 1 normal 15 N
regan 3 male 876528 urban low ncm 8 month monthly yes 1 normal 11 LESS
dharamraj 4 male 872723 urban low ncm 4 months monthly yes nil 12 N
lithika 5 female 874638 urban low cm 3 months monthly yes 1 normal 17 N
subhash 8 male 874111 urban low cm 3 years 3 months yes 1 affected 20 n
madhavan 7 male 874112 urban low cm 3 years 3 months yes 1 affected 18 n
prashanth 12 male 875835 rural low cm 7 month monthly yes 1 normal 32 n
nisha 8 female 876166 rural low cm 7 month monthly yes nil 18 n
veeramani 12 male 875701 rural low cm 18 months monthly yes 2 normal 27 n
jeyalakshmi 8 female 850147 rural low cm 5 months monthly yes 2 normal 17 n
lokesh 10 male 862467 urban low ncm 6 months monthly yes 1 normal 22 n
vijayarasu 4 male 860458 urban low cm 6 months monthly yes 1 normal 12 N
kokila 9 female 800948 rural low ncm 2 years 2 months yes 1 normal 20 n
suresh 4 male 865950 rural low ncm 1 years 2 months yes nil 14 N
asraf 2 male 850142 urban low ncm 6 months monthly yes 1 normal 12 N
abhisha 7 female 866416 rural low cm 6 months monthly yes 1 normal 15 LESS
alfara 2 female 875029 rural low ncm 4 months months yes 1 died 12 N
abu bakkar 3 male 878512 urban low ncm 6 months monthly yes 1 normal 12 N
naveen 2 male 875983 urban low ncm 1 years monthly yes 1 normal 11 N
neelavanan 3 male 875695 rural low cm 3 months monthly yes 2 dead 13 N
pugalandi 8 male 877022 rural low cm 1 years monthly yes 1 dead 20 n
thoufik 9 male 873771 urban low ncm 11 month monthly yes nil 20 LESS
diwakar 7 male 877018 rural low ncm 7 month monthly yes 1 affected 18 n
abhirami 5 female 877019 rural low ncm 6 months monthly yes 1 affected 15 n
prithika 5 female 876748 rural low cm 9 months monthly yes 1 normal 12 LESS
harish 3 male 872532 rural low ncm 1 years 2 months yes 1 normal 11 N
deep mondol 7 male 876742 rural low ncm 6 months monthly yes 1 normal 15 LESS
tejas 2 male 876628 rural low ncm 6 months monthly yes nil 10 N
dharmaraj 4 male 871213 urban low ncm 4 months montly yes nil 12 N
gugan 2 male 876444 rural low cm 6 months monthly yes nil 11 N
lokesh 4 male 874379 urban low ncm 7 month monthly yes 1 normal 14 N
thaita parveen 3 female 849807 urban low ncm 7 month 2 months yes 1 dead 12 N
allen 9 male 867458 rural low cm 6 monhs monthly yes 1 normal 22 n
raghul 6 male 862081 urban low ncm 4 months monthly yes 1 normal 16 LESS
ansari khan 4 male 875602 urban low ncm 2 years 2 months yes nil 14 N
vimal 3 male 876921 urban low cm 2 years monthly yes 2 dead 11 N
ramya 11 female 876797 rural low cm 1 years monthly yes 2 dead 20 LESS
raghava 3 male 863760 rural low ncm 5 months monthly yes nil 12 N
anbulagan 6 male 845979 rural low ncm 6 months monthly yes 1 normal 19 n
jeeva 3 male 877362 rural low ncm 6 months monthly yes 1 normal 13 N
puniya 7 female 869112 rural low cm 6 months monthly yes nil 20 n
keerthi 5 female 873674 urban low cm 11 months monthly yes 1 normal 15 LESS
devadarshan 3 male 874888 urban low cm 8 month monthly yes 1 normal 11 N
hemavathy 9 female 877456 urban low cm 7 month monthly yes 1 normal 17 LESS
nivedha 6 female 877462 rural low cm 2 years monthly yes nil 17 n
venkatesh 4 male 872417 rural low ncm 6months monthly yes I normal 15 n
pooja 3 female 875192 rural low ncm 6 months monthly yes nil 13 n
 112 
 
 
  
height < 2nd SD < 3 rd SD CENTILE BSA pallor HR RR BP temperature CVS RS liver spleen Hb MCV MCH Platelets Hb electrophoresis chest x ray
90 NO NO 10 th 0.6 yes N N N N n N 2 cm 3 cm 7 75 25 2.2 lakhs major cardiomegaly
134 NO NO Normal 0.9 yes N N N N N N 2cm 4 cm 7.7 75 25 1.8 lakhs major cardiomegay
100 YES YES less than 3rd 0.65 yes N N N N n N 5cm 6 cm 6 77 25 1.2 majpr NORMAL
96 NO NO 30 th 0.64 yes tachy N N N N N 2cm 1cm 7 76 25 2.9 lakhs major NORMAL
96 YES NO less than 3rd 0.64 yes tachy N N N N N 2m 1cm 7 77 25 2.4 lakhs major NORMAL
125 NO NO 10 th 0.9 yes tachy N N N N N 2 cm 6 cm 6 75 25 2.5 lakhs major cardiomegaly
121 NO NO 10 th 0.88 yes tachy N N N N N 3cm 4 cm 8.6 88 26 2 lakhs major cardiomegaly
97 NO NO less than 3rd 0.64 yes tachy N N N N N 3cm 4 cm 6 82 25 1.2 lakhs major cardiomagaly
91 NO NO 10 th 0.54 yes tachy N N N N N 3 cm 5cm 7 76 25 1.9 lakhs major cardiomegaly
97 NO NO Normal 0.57 yes tachy N N N N N 3cm 2 cm 10 78 38 2.6 lakhs major cardiomegaly
98 YES NO less than 3rd 0.7 yes tachy N N N N N 2cm 2cm 7.6 77 26 1.4 lakhs major NORMAL
105 YES YES less than 3rd 0.78 yes N N N N N N 2 cm 5cm 10 82 28 2.7 lakhs intermedia cardiomegaly
102 YES YES less than 3rd 0.72 yes N N N N N N 5cm  6 cm 8 77 25 2 lakhs intermedia NORMAL
145 NO NO Normal 0.7 yes N N N N N N 2 cm 4 cm 6 73 25 1.3 lakhs major cardiomegaly
103 YES YES less than 3rd 0.7 yes N N N N N N 2cm 3 cm 7 77 25 1.8 lakhs major NORMAL
130 YES YES 10 th 0.97 yes N N N N N N 2cm 4 cm 6.5 70 22 2.3 lakhs major cardiomegaly
105 YES YES less than 3rd 0.7 yes N N N N N N 2 cm 3 cm 8.9 79 26 3.43 lakhs major cardiomegaly
127 NO NO 5 th 0.88 yes N N N N N N 2 cm 3 cm 7 70 23 1.5 lakhs major cardiomegaly
97 NO NO 10 th 0.57 yes tachy N N N N N 3cm 6 cm 6 70 24 1 lakh major cardiomegaly
115 YES YES less than 3rd 0.8 yes tachy N N N N N 3 cm 10 cm 6.5 67 22 1.64 lakh intermedia cardiomegaly
99 NO NO Normal 0.62 yes N N N N N N 2 cm 4cm 6 64 24 1.4 lakhs intermedia cardiomegaly
86 NO NO Normal 0.52 yes tachy N N N N N 2cm 3 cm 6.2 78 27 3 lakhs major NORMAL
109 YES YES less than 3rd 0.66 yes tachy N N N N N 2 cm 3 cm 7 78 25 1.8 lakhs major NORMAL
87 NO NO Normal 0.52 yes tachy N N N N N 2 cm 5 cm 8.5 78 26 2 .2 lakhs major cardiomegaly
90 NO NO Normal 0.55 yes tachy N N N N N 2 cm 3 cm 7 75 25 3 lakhs major NORMAL
85 NO NO Normal 0.52 yes N N N N N N 4cm 5 cm 5.6 67 22 1,2 lakhs major NORMAL
86 YES YES less than 3rd 0.55 yes tachy N N N N N 5 cm 5 cm 6.5 72 24 2 lakhs major cardiomegaly
120 NO NO 10 th 0.82 yes N N N N N N 3 cm 3 cm 6.5 75 25 2.3 lakhs major NORMAL
122 YES YES less than 3rd 0.81 yes tachy N N N N N 3 cm 4 cm 7.4 75 25 2.5 lakhs major cardiomegaly
98 YES YES less than 3rd 0.72 yes tachy N N N N N 2 cm 7 cm 7 76 25 2 lakhs major NORMAL
117 NO NO Normal 0.69 yes N N N N N N 6 cm 7 cm 6.5 72 24 1.4 lakhs major NORMAL
112 NO NO Normal 0.64 yes N N N N N N 1 cm 3 cm 6.8 75 25 2.2 lakhs major NORMAL
91 NO NO 10 th 0.54 yes N N N N N N 2 cm 3 cm 6.7 102 31 3.16 lakhs intermedia cardiomegaly
107 YES YES less than 3rd 0.66 yes tachy N n N N N 3cm 4 cm 7.2 77 25 2.9 lakhs major cardiomegaly
90 NO NO Normal 0.51 yes N N N N N N 2cm 2 cm 8 79 30 5 lakhs major cardiomegaly
100 NO NO Normal 0.59 yes tachy N N N N N 2 cm 3 cm 10 78 38 2.6 lakhs major cardiomegaly
91 NO NO Normal 0.54 yes tachy N N N N N 2 cm 4 cm 7 75 25 3.4 lakhs major NORMAL
110 NO NO Normal 0.66 yes N N N N N N 2 cm 3 cm 8.8 77 25 3.8 lakhs major cardiomegaly
106 NO NO Normal 0.59 yes tachy N N N N N 2 cm 3 cm 9 80 30 2.8 lakhs intermedia NORMAL
125 NO NO Normal 0.89 yes N N N N N N 2 cm 5 cm 7 75 24 1.6 lakhs major cardiomegaly
110 NO NO Normal 0.7 yes N N N N N N 3 cm   4 cm 7.8 77 26 2 lakhs major cardiomegaly
105 NO NO Normal 0.64 yes tachy N N N N N 2 cm  4cm 7.5 77 25 2.6 lakhs intermadia cardiomegaly
92 NO NO Normal 0.54 yes tachy N N N N N 2 cm 1 cm 7.4 76 23 2 lakhs major cardiomegaly
122 YES YES less than 3rd 0.81 yes N N N N N N 2cm 4 cm 10 80 30 2.7 lakhs major cardiomegaly
95 YES YES less than 3rd 0.58 yes tachy N N N N N 1.5 cm 3 cm 8.8 67 28 3.2 lakhs major NORMAL
116 NO NO Normal 0.79 yes N N N N N N 2 cm 3 cm 7 75 25 2.3 lakhs major cardiomegaly
107 NO NO Normal 0.62 yes N N N N N N 2cm 4 cm 7 80 26 1.38 lakhs major NORMAL
118 NO NO Normal 0.81 yes tachy N N N N N 3 cm 4 cm 6.5 75 25 1.8 lakhs major cardiomegaly
105 NO NO Normal 0.66 yes tachy N N N N N 3 cm 6 cm 6.5 78 25 1.68 lakhs major cardiomegaly
90 NO NO 10 th 0.54 yes tachy N N N N N 2cm 4 cm 6.7 80 27 2.7 lakhs major cardiomegaly
117 YES NO Normal 0.74 yes N N N N N N 2cm 3cm 8.9 84 30 3.8 lakhs major cardiomegaly
100 NO YES less than 3rd 0.7 yes N N N N N N 2cm 5cm 8 81 31 2 lakhs major cardiomegaly
96 YES YES less than 3rd 0.62 yes tachy N N N N N 2 cm 4 cm 6.9 77 25 1. 9 lakhs major cardiomegaly
92 NO NO 10th 0.6 yes tachy N N N N N 1cm 4 cm 7 78 25 2 lakhs major cardiomegaly
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ecg RVH LVH
QT C 
interval
echo ferritin tr pht lv mass lvm/m2 lvmass >95centile
EF (NORMAL 56 % 
TO 78 %)
% fs
(28-44) trv
pericardial 
effusion
total no of 
transfusions
Normal NIL NIL N ab 1271 n mild 47 78.3 INCREASED 67 36 2.6 no 22
ab + + N ab 1750 trivial no 82 91.1 INCREASED 67 37 2.5 no 127
Normal NIL NIL N normal 290 N no 45 69.2 NORMAL 61 32 2.3 no 66
Normal NIL NIL N normal 420 trivial no 37 52.8 NORMAL 70 41 2.4 no 43
Normal NIL NIL N ab 2478 mild mild 160 250 INCREASED 67 37 2.8 no 49
ab + + N ab 2000 trivial no 137 152.2 INCREASED 74 43 2.3 no 103
ab NIL + N ab 1752 trivial no 80.1 91 INCREASED 77 45 2.2 no 101
Normal NIL + N ab 5750 mild mild 39.4 61.5 NORMAL 63 32 2.9 no 55
Normal NIL NIL N ab 2000 mild mild 174 322.2 INCREASED 71 40 2.8 no 32
Normal NIL NIL N ab 1913 trivial mild 64 106.6 INCREASED 75 41 2.4 no 44
Normal NIL NIL N ab 2135 n no 78 111.4 INCREASED 74 43 2.1 no 57
ab NIL + N ab 961 mild mild 98 125.64 INCREASED 70 42 2.4 no 20
Normal NIL NIL N normal 215 n no 49 68 NORMAL 70 58 2 no 16
ab NIL + N ab 1152 N NO 163 232 INCREASED 70 36 2.1 no 71
Normal NIL NIL N normal 1980 N NO 54.2 77.4 NORMAL 67 36 1.9 no 89
ab NIL + N ab 2942 mild no 210 216 INCREASED 68 38 2.5 no 126
ab NIL + N ab 7192 N no 88 125.7 INCREASED N N 2.5 no 91
ab NIL + N ab 1002 N no 102 115.9 INCREASED N N 2.2 no 114
ab NIL + N ab 6191 N no 77 128 INCREASED 70 41 2.5 no 42
Normal NIL NIL N ab 400 mild mild 180 225 INCREASED 55 28 2.9 no 42
ab + NIL N ab 2188 n no 220 314.2 INCREASED 71 40 2.7 no 18
Normal NIL NIL N normal 1183 mild no 43.6 71.6 NORMAL 66 39 2.5 no 18
Normal NIL NIL N ab 2878 mild no 131 187 INCREASED 66 39 2.5 plus 78
Normal NIL NIL N ab 512 mild no 52.1 100 INCREASED 64 34 2.6 no 16
Normal NIL NIL N ab 1822 trivial no 47 85.4 INCREASED 70 41 2.7 no 30
Normal NIL NIL N ab 1463 mild mild 29 52.7 NORMAL 62 33 2.7 plus 12
ab + NIL N normal 675 n no 33.3 41 NORMAL 70 41 2.1 no 33
Normal NIL NIL N ab 4277 n no 103 125.6 INCREASED 63 34 2.1 no 84
ab NIL + N ab 7610 mild no 77 95.06 INCREASED 73 35 2.6 no 97
Normal NIL NIL N normal 1086 n no 57 79.1 INCREASED 64 34 2.1 no 77
Normal NIL NIL N ab 2124 mild mild 53 76.8 INCREASED 70 39 2.6 no 54
ab NIL + N ab 3928 trivial no 58.8 91.8 INCREASED 76 44 2.4 no 51
Normal NIL NIL N normal 5382 n no 30.3 56.1 INCREASED 73 41 2.4 no 12
ab + + N ab 6750 trivial no 61.22 92.7 INCREASED 80 47 2.4 no 78
ab NIL + N ab 658 n no 49 96.7 INCREASED 70 38 2.3 no 18
ab NIL + N ab 1913 N no 88 149.1 INCREASED 78 46 2.4 no 44
Normal NIL NIL N normal 1998 trivial no 19.28 35.1 NORMAL 75 40 2.6 no 18
Normal NIL NIL N normal 1986 n no 42 60 INCREASED 75 43 2.3 no 41
Normal NIL NIL N normal 305 n no 27 45 NORMAL 80 48 2.3 no 15
Normal NIL NIL N normal 915 trivial no 71.8 80.89 INCREASED 74 43 2.5 no 102
Normal NIL NIL N normal 976 n no 64 91.4 INCREASED 69 38 2.3 no 68
Normal NIL NIL N ab 5910 mild mild 60.13 93.9 INCREASED 63 32 2.6 no 12
Normal NIL NIL N normal 2011 trivial no 52.31 96.8 INCREASED 73 41 2.6 no 12
Normal NIL NIL N N 3959 n no 66.76 82.4 INCREASED 71 40 2.1 no 120
Normal NIL NIL N normal 569 trivial no 30.12 50 NORMAL 70 38.6 2.5 no 31
ab NIL + N N 4279 N no 91.34 114.1 INCREASED 72 40 2.4 no 66
Normal NIL NIL N normal 1578 N no 28.64 47.6 NORMAL 75 40 2.2 no 30
ab NIL + N ab 3321 trivial mild 90.03 111.1 INCREASED 76 44 2.6 no 78
Normal NIL NIL N ab 2505 N no 56.46 76.3 INCREASED 82 49 2.1 no 49
Normal NIL NIL N ab 9843 N no 98.3 163.3 INCREASED 63 34 2.2 no 28
Normal NIL NIL N ab 1124 trivial mild 77.01 104 INCREASED 80 48 3.1 no 101
Normal NIL NIL N ab 5813 mild mild 56.12 80.17 INCREASED 63 34 2.8 no 48
ab nil plus N ab 5917 n no 44.8 72.2 INCREASED 63 33 2.3 no 42
Normal nil nil N ab 600 n no 38.9 64.3 INCREASED 62 40 2.2 no 30
